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Blood transfusion is the process of transferring blood or blood components from one 
individual into the circulatory system of another. Blood transfusions can be life-saving 
after massive blood loss during trauma or surgery or can be used to treat chronic blood 
diseases such as anemia and thrombocytopenia. Unfortunately, these therapeutic 
effects can be accompanied by transfusion complications that involve the recipient’s 
immune system. Since the immune system is educated to distinguish self from non-self 
molecules (1), non-self molecules present in the blood product can activate the 
recipient’s immune system.  
Besides immune activation, blood transfusions can modulate or suppress the recipient’s 
immune system resulting in tolerance. Already in 1953, Billingham, Brent and 
Medawar showed that infusion of donor cells in a newborn mouse induces lifelong 
immunological tolerance in a proportion of animals towards the donors’ organs (2). 
Twenty years later, an enhanced graft survival was observed in kidney transplant 
recipients who had received pretransplant blood transfusions (3). During the last 
decades, the beneficial effects of pretransplant blood transfusions are overshadowed by 
other approaches to improve graft survival (4). Better patient care, compatibility 
between patient and organ donor and in particular the use of new generation 
immunosuppressive drugs all positively affect transplantation outcome. However, 
transplant rejection and health problems due to side effects of immunosuppressive 
drugs remain a problem and there is still need for strategies that induce a state of 
tolerance in the recipient. In this thesis we questioned whether a pretransplant blood 
transfusion may be part of such a strategy in patients that undergo simultaneous 
pancreas-kidney transplantation (SPKT).  
After a short description of the history of blood transfusions and some general 
immunological aspects, this introduction will give an overview of the immunological 
and clinical effects of pretransplant blood transfusions.  
 
2. HISTORY OF BLOOD TRANSFUSIONS 
 
In the early 17th century, attempts were made to transfuse humans with animal blood 
but this resulted in severe complications and high mortality rates. Blood transfusions 
were abandoned or even prohibited in some countries, until 1816 when John Leacock 
and James Blundell established that for successful blood transfusion donor and 
recipient must be of the same species (5). The occurrence of severe transfusion-related-
complications in the majority of patients urged intensive research on blood transfusion 
again. In 1900 and 1901, Landsteiner discovered the ABO erythrocyte blood group 
system. After mixing blood from two individuals, he observed aggregates of red blood 
Chapter 1 
10 
cells in some combinations. He attributed this phenomenon to inherited individual 
differences and described the human blood groups A, B and O, followed by AB a year 
later (6). However, some patients still suffered from severe transfusion reactions during 
transfusion of compatible blood. Another important breakthrough was the discovery of 
the Rhesus (Rh) blood group system in 1940 (7). The existence of two distinct 
expression patterns of the RhD antigen on the surface of red blood cells (expression or 
not) also elucidated the etiology of hemolytic neonatal disease. The transfusion of ABO 
and RhD compatible blood to a patient reduced the incidence of dangerous hemolytic 
complications considerably. The transfusion of whole blood, which occurred until the 
1960s, includes the transfer of donor white blood cells (leukocytes) to the patient. In the 
early 1950s, leukocyte antigens were discovered by agglutinating antibodies present in 
the sera of multitransfused and multiparous women suffering from febrile non-
hemolytic transfusion reactions (8-11). It was soon found that these human leukocyte 
antigens (HLA) play an essential role in the human immune response and in transplant 
rejection. The correlation between the presence of leukocyte agglutinins and febrile 
transfusion reactions (12) was the basis for removal of leukocytes from blood 
transfusions for patients on dialysis or with blood diseases. In 1962 antibodies against 
HLA antigens were identified as a cause for platelet transfusion refractoriness. In the 
seventies blood component therapy was introduced that separated red blood cells 
(RBC), plasma and the buffy-coat by centrifugation. Removal of the buffy-coat, 
containing 50-80 percent of leukocytes and >90 percent of platelets, and the 
development of specialized leukocyte-reducing filters decreased the incidence of 
leukocyte-related complications considerably (13). However, in 1973 the importance of 
leukocytes in the immunomodulatory effect of pretransplant blood transfusions was 
recognized (14).    
 
3. THE HUMAN IMMUNE SYSTEM 
 
3.1 The immune response 
Leukocytes are the principal cells of the immune system. They are able to ensure 
proper recognition and destruction of non-self molecules, such as bacteria and viruses, 
while responses to self molecules do not occur as these can cause autoimmune 
phenomena (1). In the absence of a functioning immune system, even minor infections 
can have a fatal outcome. However, this immune system is a barrier for blood 
transfusion therapy and transplantation. Foreign molecules (alloantigens) and cells 
present in the blood product or transplanted organ can activate the recipient’s immune 
system leading to transfusion complications or transplant rejection. The human 
immune system can be divided into the innate, non-antigen specific, immune system 
and the acquired, antigen-specific adapted, immune system.  
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3.1.1 Innate immunity 
After passing the physical barriers of the skin and mucosal epithelia of the respiratory, 
gastrointestinal and reproductive tracts, the innate immune system provides an 
immediate, but non-specific response to invading pathogens. Proteins of the 
complement system that circulate in the blood or are locally produced will opsonize 
and kill particular pathogens. Cellular barriers of the innate immune system include 
natural killer (NK) cells, mast cells, basophils, eosinophils and phagocytes 
(macrophages, neutrophils and dendritic cells). NK cell activation is regulated by a 
balance between signals mediated through activating and inhibitory killer 
immunoglobulin-like (KIR) receptors (15). Inhibitory KIRs recognize the absence of self 
human leukocyte antigens (HLA) of the class I type (missing-self hypothesis) (16). In 
the absence of these ligands, such as in virus-infected host cells or transplanted donor 
cells (17), the balance shifts towards NK cell activation that may result in cytotoxicity. 
Phagocytes are able to engulf pathogens followed by the release of enzymes and acids 
that kill and digest the pathogen. Innate immune cells, like NK cells and dendritic cells, 
are also important mediators in the activation of the acquired immune system (18).  
Blood transfusions interfere with the innate and acquired immune system. In stored 
blood products, granulocytes and macrophages deteriorate and become apoptotic or 
necrotic. Apoptotic cells, expressing annexin V/phosphatidylserine are engaged by 
macrophages that start to produce anti-inflammatory cytokines such as prostaglandin 
E2 and TGF . These factors suppress the proinflammatory innate immune response of 
macrophages and NK cells (19,20) and impair the function of dendritic cells, thereby 
influencing the acquired immune response as well (21).  
 
3.1.2 Acquired immunity 
The acquired immune system is antigen-specific and involves a cellular and humoral 
component. The cellular immune response is mediated by T lymphocytes. Via their T 
cell receptor (TCR), T cells specifically recognize the target antigen that is presented by 
professional antigen presenting cells (APCs), such as dendritic cells, B cells and 
macrophages. These APCs use molecules of the major histocompatibility complex 
(MHC), the human leukocyte antigens (HLA) in humans, for proper antigen 
presentation (22). T cells can activate other immune cells or become cytotoxic. Key 
players of the humoral immune response are B lymphocytes that carry an 
immunoglobulin receptor. Their principal function is the production of alloantibodies 
directed against soluble or cell surface antigens. Once T and B cells are triggered, a 
proportion of them will become memory cells. The memory cells will induce a fast and 
strong immune response upon a subsequent encounter with the antigen.  
Blood transfusions contain many foreign antigens that can activate recipient T and B 
cells. Alloantigens can involve donor red blood cell molecules, foreign HLA molecules 
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or any other antigen present in the blood donor and not in the recipient. With 
increasing storage intervals of blood products, the quality of APCs deteriorates leading 
to a diminished ability to activate recipient T cells (21). Moreover, leukocyte-derived 
soluble factors accumulate in blood components upon storage. Pro-inflammatory 
cytokines, like interleukin (IL)-1, IL-6 and IL-8, activate recipient immune cells that may 
cause transfusion complications (23), whereas soluble HLA class I and II molecules and 
soluble Fas-ligand (FasL) may impair the function of T cells (24).  
 
3.2 Human leukocyte antigens 
Although the molecules of the HLA system were initially recognized as targets for 
immunological attack after blood transfusion and transplantation, the primary 
physiological role of HLA is to present peptides to T cells, thereby initiating the 
acquired immune response. The HLA system is the most polymorphic system 
described in humans (25,26). The high degree of polymorphism provides the human 
species with the best protection against the wide range of pathogens, as at least some 
individuals will carry the proper HLA molecule that can present pathogenic peptides 
to the immune system. The inheritance of two different sets of HLA molecules (one 
haplotype from the father and one from the mother) will further amplify this. Based on 
their structure and function in the immune response, HLA molecules are divided into 
two groups: class I and class II. HLA molecules are encoded by a cluster of genes 
located on the short arm of chromosome 6 (27).  
 
3.2.1 HLA class I molecules 
The classical HLA class I molecules (HLA-A, -B and -C) are composed of a heavy -
chain linked to a non-polymorphic light chain, 2 microglobulin, that stabilizes the 
complex (28). The -chain consists of five domains: two peptide-binding domains ( 1 
and 2), one immunoglobulin-like domain ( 3), the transmembrane region and the 
cytoplasmic tail (Figure 1A). The 1 and 2 domains are the most polymorphic and 
they form a peptide-binding groove for antigenic peptides of eight to ten amino acids 
in length that are primarily derived from endogenous proteins like self proteins or 
virus-induced proteins (29). All nucleated cells and platelets express HLA class I 
molecules and can be a target of an immune response. In circulating blood, about 70% 
of HLA class I antigens is expressed on platelets.  
 
3.2.2 HLA class II molecules 
The HLA class II molecules (HLA-DR, -DQ and -DP) consist of an -chain and a -
chain, which form a heterodimer. Each chain consists of four domains: the peptide-
binding domains ( 1 and 1), an immunoglobulin-like domain ( 2 and 2), the 
transmembrane region and the cytoplasmic tail (Figure 1B). The majority of the 
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polymorphism is located in the 1 domain of the HLA-DR molecules and in the 1 and 
1 domains of the HLA-DQ and -DP molecules (30). These domains form a peptide-
binding groove, which, in contrast to class I molecules, is open at both sides and can 
accommodate peptides of 13 to 25 amino acids in length (31). The peptides that bind to 
HLA class II molecules are mainly of exogenous origin. Before loading into HLA class 
II molecules as antigenic peptides, foreign proteins need internalization and processing 
by professional antigen presenting cells (APCs). HLA class II molecules are 
constitutively expressed on APCs, such as dendritic cells (DCs), macrophages and B 














Figure 1: HLA class I (A) and HLA class II (B) molecules.   
 
 
3.3 The activation of T cells 
The HLA class I and class II molecules play a different role in T cell responses. The 
main function of HLA class I molecules is to present foreign peptides to CD8+ T cells 
that can mount a cytotoxic response (32). In contrast, the HLA class II-peptide complex 
is recognized by CD4+ T cells (33) that generally function as T helper cells. The structure 
of T cells that recognizes HLA molecules is the membrane-bound T cell receptor (TCR). 
The TCR complex of most T cells consists of an  and  chain that form a heterodimer 
and are linked to the non-polymorphic CD3 complex (34). A minority of T cells 
expresses a TCR composed of a  and  chain. These  T cells possess some innate 
immune cell characteristics, such as the ability of recognizing microbial and lipid 
antigens without the need for presentation into HLA molecules (35). Besides triggering 
the TCR/CD3 complex (signal 1), T cells need co-stimulatory signals (signal 2) to 
become activated.  
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3.3.1 Direct versus indirect allorecognition  
T cells can recognize HLA molecules via the direct or indirect pathway. Direct 
allorecognition (Figure 2A) refers to the recognition of intact allogeneic HLA class I and 
II molecules on the surface of donor APCs and is restricted to blood transfusion, 
transplantation and pregnancy. The strength of this type of immune response, as 
measured by precursor frequency of T cells, is about 100-fold higher than that of T cells 
recognizing alloantigens indirectly (36). Although the thymus only selects cells bearing 
self-HLA molecules, the structural similarity between the TCR contact surfaces of many 
HLA molecules may account for a situation in which an allogeneic HLA molecule with 
a peptide mimics self-HLA restriction (37).  
Transfused donor APCs can give rise to direct allorecognition and trigger recipient T 
cells. Platelets express HLA class I molecules, but cannot activate T cells directly in the 
absence of donor APCs (38). Leukocyte-depletion and storage of the blood product can 
diminish the occurrence of direct allorecognition. In transplantation, the direct 
allorecognition pathway predominates in the first few weeks to months after 
transplantation and is the main cause of acute graft rejection (39,40). With elapsing time 
after transplantation, donor APCs fade away and the role for the indirect 














Figure 2: Direct (A) and indirect (B) allorecognition pathway. 
 
 
The indirect pathway of allorecognition reflects the normal mechanism of T cell 
stimulation by nominal antigens. Indirect allorecognition (Figure 2B) is the recognition 
of alloantigens in the context of self-HLA molecules present on self-APCs. Upon blood 
transfusion or transplantation, alloantigens are shed from donor cells or the graft, taken 
up by recipient’s APCs, degraded into peptides and presented in the groove of HLA 
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class II molecules to CD4+ recipient T cells. Alloantigens can be derived from any 
protein present in the blood or organ donor and not in the recipient, but mainly 
involves the HLA molecules and minor histocompatibility antigens (41).  
After blood transfusion or transplantation, self-APCs are permanently active to pick up 
donor-derived alloantigens and present these to recipient T cells. Evidence for the 
indirect pathway of allorecognition after transplantation came from observations that 
graft rejection still occurred in the absence of immunogenic donor-derived passenger 
cells in the graft (42). It is the dominant allorecognition pathway long after 
transplantation (43) and mainly associated with chronic graft rejection (44-47), which 
explains the need for life-long immunosuppressive drug use.   
 
3.3.2 Co-stimulation  
The interaction between co-stimulatory molecules on the membrane of the APC and the 
T cell leads to the development of an effective immune response. Two well-known co-
stimulatory pathways are the CD28-B7 pathway and the CD40-CD40L pathway (48,49). 
Interaction between receptor and ligand will lead to full activation of the T cell. Upon 
activation, the T cell will synthesize and secrete interleukin (IL)-2, which drives clonal 
expansion and differentiation of the activated cell. To control the process of expansion 
of activated T cells, also inhibitory signals are necessary. Cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) is homologues to CD28, but is an important negative 
regulator of T cell responses (50,51). Its expression is rapidly up regulated following T 
cell activation and results in termination of the T cell response.  
 
3.4 Effector mechanisms 
 
3.4.1 T cells 
After engagement of the TCR and co-stimulatory signal, naïve CD4+ and CD8+ T cells 
can differentiate into effector cells, regulatory T cells and memory cells.  
The cytokines secreted by APCs determine the skewing of effector CD4+ T cells into T 
helper 1 (Th1) or Th2 cells. Generation of Th1 cells requires the presence of interferon  
(IFN- ) and interleukin (IL)-12. These cytokines cause the Th1 cells to produce IFN-  
and tumor necrosis factor-  (TNF- ), thereby increasing the killing efficacy of 
macrophages and the proliferation of cytotoxic CD8+ T cells. Differentiation into Th2 
cells will occur in the presence of IL-6 or IL-4, of which the latter can be released by NK 
cells. Th2 cells produce IL-4, IL-5 and IL-13 that will stimulate B cells to produce 
antibodies and will attract and activate eosinophils (52). Upon recognition of donor 
HLA class I antigens in presence of Th1 cytokines, CD8+ T cells acquire cytotoxic 
properties that enable them to kill their targets via the release of cytotoxic effector 
molecules, like perforin and granzymes, or via Fas-Fas ligand interaction (53).  
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3.4.2 B cells 
Th cells are important initiators in the production of alloantibodies by B cells (54). B 
cells can bind and internalize donor antigens by their surface immunoglobulin 
receptor, cleave them into allopeptides and load the suitable ones into their own HLA 
class II molecules on the surface. However, these alloreactive B cells require a cognate 
interaction of Th cells to get activated. Upon antigen recognition by the T cell and 
engagement of CD40 on the B cell with CD40L on the T cell, the B cell will be able to 
divide and develop into an antibody producing plasma cell.  
Antibodies directed against donor HLA antigens are often responsible for 
complications after blood transfusion and rejection of the transplanted organ, via 
complement activation or antibody-dependent cell cytotoxicity (55).  
 
3.5 Immune regulation 
Regulation of normal immune responses involves central and peripheral mechanisms. 
Central tolerance results from thymic deletion of T cells that have the potential to 
respond to self antigens in a process called negative selection. As not all autoantigens 
may be present in the thymus and some cells may escape central deletion, multiple 
mechanisms contribute to tolerance in the periphery. Peripheral tolerance to 
autoreactive or alloreactive T cells can occur through clonal anergy, clonal deletion or 
active suppression or killing of alloreactive cells by regulatory cells (56).  
T cells can become functionally inactive (anergic) when they are activated through the 
TCR in the absence of appropriate costimulatory signals (57) or through signaling via 
alternative receptors, like CTLA-4 (58,59). Clonal deletion can occur through persistent 
activation of the TCR that leads to activation-induced cell death (AICD). An important 
mechanism underlying the AICD in CD4+ T and B cells is the ligation of the Fas death 
receptor expressed on their surfaces by its ligand (FasL) on CTLs (60).  
Active suppression of T cells can occur by particular populations of cells, including 
dendritic cells (DCs) and regulatory T cells. DCs, the most potent APCs, can also 
induce T cell tolerance, dependent on their maturation state. Antigen presentation by 
immature DCs is associated with induction of tolerance, due to the expression of low 
levels of HLA class II molecules and costimulatory molecules resulting in poor 
stimulation of T cells (61). Regulatory T cells (Tregs) can be derived from the thymus or 
arise as a result of tolerogenic factors present in the environment. The thymus-derived, 
naturally occurring regulatory CD4+ T cells express high levels of the IL-2 receptor  
chain, CD25 (62). These CD4+CD25+ T cells can suppress proliferation of other cells in a 
non-antigen-specific manner (63) and require direct cell-cell contact (64). The 
phenotypic markers CTLA-4 and forkhead box P3 (Foxp3) are associated with Tregs 
(65,66), but are not thought to be exclusive. The peripherally induced CD4+ Tregs, Tr1 
and Th3, exert their suppressive function via IL-10 and TGF  (67,68). CD8+ suppressor 
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T cells that lack CD28 expression (69), are able to induce the expression of inhibitory 
receptors, such as immunoglobulin like transcript 3 (ILT3) and ILT4, on APCs, 
rendering them tolerogenic and unable to stimulate CD4+ T cells (70).  
 
4. CLINICAL CONSEQUENCES OF EXPOSURE TO FOREIGN HLA 
MOLECULES 
 
4.1 Blood transfusion 
The allogeneic character of blood transfusions can elicit harmful effector responses in 
the recipient. On the other hand, blood transfusions can lead to transfusion-related 
immunomodulation (TRIM) that encloses intended but also unintended effects (71).  
 
4.1.1 Immune activation 
Because erythrocyte transfusions are matched for ABO and RhD antigens, most adverse 
effects of blood transfusions can be attributed to differences in HLA. Adverse effects 
are primarily caused by HLA class I and class II antibodies produced by the recipient 
upon confrontation with donor leukocytes. Blood transfusion can also activate the 
alloreactive T cell compartment and increase the number of helper T cells and cytotoxic 
T cells (72,73), but the clinical sequelae are less clear.   
The formation of HLA alloantibodies by the recipient (HLA immunization) depends on 
the blood product, recipient and donor (71). Characteristics of the blood product that 
favor immunization include the high number of viable leukocytes (74) and shorter 
storage intervals (21,24). Also the degree of HLA disparity determines immunization 
outcome in transfused patients. In case of two HLA class II mismatches, more frequent 
and broader HLA antibodies are developed, while sharing of an HLA haplotype or 
HLA-DR molecule results in less antibody formation and a lower CTLp frequency 
(75,76). Patients that have already developed alloantibodies due to previous 
confrontation with foreign HLA can boost such alloantibodies upon weaker 
stimulation. HLA alloantibodies form a major problem for patients that depend on 
platelet transfusions by causing immune destruction of transfused incompatible 
platelets, resulting in immune refractoriness to random donor platelet transfusions. 
Moreover, preformed HLA alloantibodies can destruct leukocytes in a subsequently 
transfused product and cause febrile non-haemolytic transfusion reactions (FNHTR).  
Donor reactivity towards the recipient can result in two other severe transfusion 
complications. Transfusion-related acute lung injury (TRALI) is a complication 
resulting in pulmonary edema. It is caused by antibodies against HLA, granulocyte or 
monocyte antigens that can be found in the plasma of transfused blood components. 
Transfusion-associated graft-versus-host disease (TA-GVHD) is a lethal, but not 
common, complication and occurs in immunocompromised patients. Within five days 
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after transfusion, proliferating lymphoid blast cells of donor origin can be found in the 
recipient’s circulation (77). These cells can mount an immune response upon 
recognition of HLA or minor histocompatibility antigens expressed on host cells and 
often results in death of the patient (77). TA-GVHD can be prevented by gamma 
irradiation of cellular blood products that prevents proliferation of donor lymphocytes 
after stimulation by recipient cells (78).  
 
Table 1: Observed clinical effects after allogeneic blood transfusions.  
Immune activationa TRIMb
HLA immunization Enhanced survival of transplanted organs 
Febrile non-haemolytic transfusion reactions 
(FNHTR) 
Cancer recurrence 
Platelet transfusion refractoriness Increased incidence of postoperative infections 
Transfusion-related acute lung injury (TRALI) Increased short-term mortality in cardiac surgery 
Transfusion-associated graft-versus-host disease 
(TA-GVHD) 
 
a Occurring in individual patients 
b Estimated from studies in patient cohorts  
 
 
4.1.2 Transfusion-related immunomodulation 
Besides immune activation, allogeneic blood transfusions can suppress or modulate the 
recipient’s immune response, referred to as transfusion-related immunomodulation 
(TRIM) (79).  
Immunosuppressive effects of allogeneic blood transfusions were reported over 30 
years ago in patients who had undergone renal transplantation. This improved 
transplant outcome after allogeneic blood transfusions was frequently observed in the 
clinic but is not mechanistically clarified (see paragraph 5). If allogeneic blood 
transfusions were able to down-regulate the recipient’s immune system, it was feared 
that they might also decrease the mechanisms of cancer immune surveillance (80). In a 
meta-analysis, the hypothesis that perioperative allogeneic blood transfusions have a 
detrimental effect on recurrence of colorectal cancer was supported, but a causal 
relationship cannot be claimed due to wide differences in design and study population 
(81). Furthermore, blood transfusions during surgery come in a late phase of the 
disease, when immune surveillance already had its chance and failed. In addition, a 
large number of observational studies in humans found an increased incidence of 
postoperative bacterial infections after allogeneic blood transfusions. Again, a causal 
effect cannot be considered proven, but it cannot be excluded either (82,83). Until now, 
a deleterious effect of allogeneic leukocyte-containing blood transfusions is most 
consistently found in cardiac surgery and is associated with higher mortality due to 
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multiple organ failure (84). The clinical effects associated with allogeneic blood 
transfusions are summarized in Table 1.  
 
4.1.3 Leukocyte-depletion 
In order to obtain more pure blood products and reduce the occurrence of unintended 
effects, leukocyte-reducing strategies have been developed. From 1960 onwards, red 
blood cell and platelet blood transfusions have been (partially) leukocyte-depleted. 
From the late 1970s, additional methods and filters were developed that improved to 
decrease the number of leukocytes. The numbers of remaining leukocytes in red blood 
cell products are summarized in Table 2. Universal leukocyte-depletion (by filtration) 
of therapeutic blood products in the Netherlands was introduced in 2001 and based on 
the theoretical risk of transmitting variant Creutzfeldt-Jakob disease (85).  
 
Table 2: Leukocyte numbers in red blood cell products. 
Blood product Leukocytes per unit (x109)
Whole blood (WB) 3 
Plasma-reduced, red blood cell concentrate (RBC) 3 
Buffy coat-depleted blood (BCD) 0.7-1.3 
By-filtration-leukocyte-reduced blood (FLR) <0.001 
 
 
The depletion of leukocytes has led to several clinical benefits. It lowers the incidence 
of HLA immunization (74), platelet refractoriness (86) and FNHTR (87) considerably. 
However, approximately 15-20% of the recipients of leukocyte-depleted red blood cell 
or platelet transfusions still produce HLA alloantibodies (88). This can be due to the 
small number of remaining leukocytes in the blood product (38) or the indirect 
recognition of platelet-derived HLA class I alloantigens. In cardiac surgery, the 
incidence of mortality was significantly decreased in patients who received leukocyte-
depleted blood products (84). On the contrary, leukocytes seemed to be required for the 
beneficial effect of allogeneic blood transfusions in transplant patients (14). 
 
4.2 Transplantation 
Upon transplantation the recipient is confronted with donor HLA class I molecules 
present on tissue cells and HLA class II molecules on passenger donor leukocytes in the 
graft. A major concern is the formation of HLA alloantibodies. Preformed HLA 
alloantibodies can cause graft rejection, but also HLA alloantibodies that develop 
during the lifetime of an allograft. By performing a cross-match before transplantation 
with donor cells and the patients’ serum, antibodies can be detected. A positive cross-
match, due to complement fixing HLA antibodies of the IgG class, is considered a 
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contraindication for transplantation (89). Graft rejection can be divided into three types: 
hyperacute, acute and chronic rejection.  
 
4.2.1 Transplant rejection 
Hyperacute rejection occurs within minutes or hours after transplantation and is 
mediated by existing antibodies. ABO and/or HLA alloantibodies can bind to 
endothelial cells on the graft and activate the complement pathway (90). Acute rejection 
is primarily a T cell mediated process and occurs within the first 3 months after 
transplantation. T cells are the main cellular infiltrate seen in the biopsies of acute 
rejected grafts and the current immunosuppression protocols directly target these T 
cells. Recently it was found that biopsies taking during acute rejection episodes also 
showed positive staining for the complement product C4d, which suggests a role for 
antibodies in acute rejection as well (91). In kidney transplantation, chronic rejection is 
currently the most prevalent cause of transplant failure (92). It develops months or 
years following transplantation and is characterized by a slow deterioration of graft 
function. The exact pathogenesis of chronic rejection is incompletely understood and 
thus treatment is difficult. It is presumed that indirect allorecognition is the 
predominant immunological driving force able to induce chronic cellular and humoral 
effector mechanisms (93,94).    
 
4.2.2 HLA matching and immunosuppressive drugs 
Matching for HLA molecules between donor and recipient improves kidney and heart 
allograft survival, with the strongest beneficial effect for matching the HLA-DR 
molecules (95-98). However, due to the enormous polymorphism of HLA, matching is 
in most cases not possible (25,26).  
Immunosuppressive drug therapy is necessary in genetically non-identical transplant 
patients. Immunosuppressive agents act by inhibition of various steps of the T cell 
activation pathway and are used as induction, maintenance or rejection therapy. 
Induction therapy is an intense, prophylactic therapy given at the time of 
transplantation to reduce acute rejection in the first days to weeks after transplantation 
(99,100). Maintenance therapy usually consists of a combination of agents and has to be 
used lifelong. Nowadays, immunosuppressive protocols tend to minimize or withdraw 
the use of these agents as they all act nonspecifically (101). They are associated with 
serious side effects, such as an increased risk of infections and certain malignancies 
(102,103). Therefore, the ultimate goal is to achieve and maintain specific 




5. IMMUNOMODULATION BY PRETRANSPLANT BLOOD  TRANSFUSIONS 
 
5.1 The blood transfusion effect 
Allogeneic blood transfusions have been associated with transplantation tolerance, 
since the observation in 1973 by Opelz and colleagues of improved kidney graft 
survival in patients who received multiple transfusions from random donors (3). Better 
graft survival was associated with an increased number of transfusions in a dose-
dependent manner (104). It was presumed that the appearance of HLA alloantibodies 
in multi-transfused patients accounted for the improved graft survival by selection of a 
cross-match negative graft. However, in 1979 it turned out that a single blood 
transfusion was also able to improve graft survival, but requires the presence of 
leukocytes (14). After this observation, research focused on the need for HLA 
compatibility between blood donor and recipient. Patients transfused with, fresh or 
frozen, (partly) HLA-DR shared blood showed an enhanced kidney or heart allograft 
survival compared with patients that received a HLA-DR mismatched transfusion 
(75,105). Moreover, the incidence of HLA immunization and CTL formation was lower 
in recipients of an HLA-DR matched transfusion as compared with an HLA-DR 
mismatched transfusion (106,107). An additional requirement for the beneficial effect 
seems to be HLA class II disparity on the other haplotype (108).  
An overview of studies that investigated the effect of pretransplant blood transfusions 
on the function and survival of organ transplants from deceased donors is given in 
Table 3. Although the beneficial transfusion effect seems to be present despite the use 
of modern immunosuppressive drugs, deliberate pretransplant transfusions are 
currently virtually abandoned. The main reasons are concern for the development of 
HLA alloantibodies that hamper transplantation in the living-related setting and the 
transmission of infectious diseases.  
 
In living-related kidney transplantation, pretransplant blood transfusions are applied 
with blood from the prospective organ donor. This protocol was initiated in an attempt 
to select potentially successful transplants by measuring the HLA sensitization rate 
after donor-specific blood transfusions (DST). It turned out that these DST improved 
graft outcome as well (126,127). However, a major risk factor is the development of 
HLA alloantibodies upon transfusion that hamper transplantation with that specific 
donor. To prevent this HLA immunization, most DST were administered under the 
coverage of various types of immunosuppressive drugs. There are two possible 
mechanisms of the success of the donor-specific transfusion protocol. A first 
explanation may be the process of selection, while this protocol separates responders 
from non-responders by means of monitoring the specific antibody response after 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2 Immunomodulatory mechanisms 
Although possible mechanisms of immunomodulation have been extensively studied, 
it is still not known how blood transfusions can down-regulate the alloimmune 
response upon transplantation.  
The mechanisms that have been proposed are based on the suppression of alloreactive 
recipient innate and acquired immune cells that may be harmful for the subsequent 
organ transplant (Table 4) (128,129).  
 
Table 4: Proposed mechanisms of the blood transfusion effect. 
Clonal deletion of alloreactive cells (apoptosis) 
Anergy induction of alloreactive immune cells 
Polarization of the immune system towards a Th2 response 
Induction of suppressor cells 




Basically, these mechanisms are based on the elimination or inactivation of recipient 
immune cells. Elimination of potentially reactive recipient T cells can occur when 
soluble molecules, such as soluble FasL (sFasL) and soluble HLA molecules, are 
released by stored donor cells in the blood product (24). 
sFasL can induce apoptosis of recipient cells by binding to Fas molecules expressed on 
recipient NK cells and cytotoxic T cells (130). Soluble HLA molecules can enter the 
recipient’s thymic circulation and cause clonal deletion of alloreactive recipient T cells 
(131).  
Inactivation of recipient immune cells can occur when they become unresponsive 
(tolerant) for activation signals or when other cells suppress their action. It is reported 
that storage of blood products favors tolerance induction, while donor leukocytes 
change and APC lose their ability to deliver proper co-stimulatory signals upon storage 
(21). This can lead to the induction of a state of anergy, which is characterized by 
unresponsiveness of alloreactive recipient T cells. Moreover, stimulation by allogeneic 
blood transfusions can skew the recipient immune system towards a Th2 phenotype. 
Cytokines produced by Th2 cells (IL-4, IL-5 and IL-13) and TGF  are capable of down-
regulating Th1 activities, such as antigen processing, macrophage activation and 
cytotoxic T cell activation (132). 
The sharing of HLA-DR molecules between blood donor and recipient can also 
promote tolerance. In an experimental setting, more IL-10 secretion and efficient IFN  
and TNF  inhibition was found after activation of responder cells with an one-HLA-
DR matched donor as compared with a complete mismatched donor (133). 
Additionally, it is suggested that donor APCs that share an HLA-DR molecule with the 
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recipient induce regulatory T cells that may suppress an immune response towards the 
subsequently transplanted organ (see also chapter 3) (134,135).  It is thought that 
suppressor T cells, or regulatory T cells, play an important role in transplantation 
tolerance (136). Also anti-idiotypic antibodies and blocking antibodies after transfusion 
are described that can fulfill a role in tolerance induction (137,138).  
A feature of tolerance may be the persistence of a low percentage of donor cells in the 
recipient after transfusion (microchimerism) (139-141). It is not exactly known if it is a 
cause or effect of immunologic tolerance, but it is thought that a tolerant state must 
exist in order for donor cells to persist. In patients that have a profound suppression of 
the innate immune system due to trauma or surgery (142), donor leukocytes can persist 
for many years, even after leukocyte-depleted blood transfusions (143). Partially (HLA-
DR) shared allogeneic cells favor microchimerism and can be detected in the recipient’s 
circulation up to eight weeks after transfusion (144). 
 
6. AIM OF THIS THESIS  
 
The initial reports on the beneficial effects of allogeneic blood transfusions upon organ 
transplantation in humans go back to the early 1970s. From that time, several studies 
attempted to confirm these effects and speculate about the mechanisms. Since the 
generation of new immunosuppressive drugs questioned the additional benefits of 
pretransplant allogeneic blood transfusions, many centers discontinued the 
administration of blood before transplantation. Our center continued this procedure for 
patients on the waiting list for simultaneous pancreas-kidney transplantation (SPKT). 
In Chapter 2 we showed that in this patient population an HLA-DR shared blood 
transfusion was able to diminish the severity of acute rejection episodes after SPKT. 
The need for HLA-DR sharing, as shown in the literature and in our study, suggests a 
role for the indirect allorecognition. Our hypothesis focuses on the role of indirect 
allorecognition after transfusion in improved transplantation outcome and is discussed 
in Chapter 3. To be able to investigate T cells with indirect allospecificity before and 
after a pretransplant protocolled blood transfusion, we aimed to develop an in vitro 
model for the indirect allorecognition. Our results, together with the possibilities and 
pitfalls of current approaches to measure indirect recognition of alloantigens are 
discussed in Chapter 4. Blood transfusions are able to activate as well as modulate the 
recipient’s immune system, but the requirements for each direction are not known. To 
determine the different effects of blood transfusions, we obtained blood from patients 
before and after a transfusion with fresh, leukocyte-rich blood from a donor matched 
for one HLA-DR antigen. Additionally, blood was obtained from patients that received 
another type of pretransplant transfusion, i.e. a donor-specific transfusion (DST), in the 
living-related kidney transplantation setting.  
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Results of stimulation of patient cells with donor and third party as measured by 
current read out systems are described in Chapter 5. In order to be able to determine 
the incidence of chimerism after an HLA-DR shared blood transfusion containing 
leukocytes, different techniques were compared to monitor the presence of donor cells 
after transfusion (Chapter 6). Finally, results of this thesis are summarized and 
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Pretransplant protocolled blood transfusions (PBTs) have been associated with less 
acute rejections and improved graft survival after kidney and heart transplantation. 
This study investigated the effect of a PBT in patients who underwent simultaneous 
pancreas-kidney transplantation and whether this effect is influenced by induction 
therapy with anti-T cell reagents. In this retrospective study spanning 10 years, we 
compared clinical outcome (acute rejection of the kidney within 6 months post-
transplant) of patients who received an one HLA-DR matched blood transfusion (n=49) 
with patients who did not receive a PBT (n=69). Occurrence of acute rejection episodes 
was not affected by PBT, however multivariate analysis identified a PBT as the major 
factor for decreasing the risk of occurrence of more severe acute rejections requiring 
ATG treatment (hazard ratio: 0.385, 95% CI: 0.186-0.796). Although 
immunosuppressive induction therapy significantly reduced acute rejection episodes 
(hazard ratio: 0.478, 95% CI: 0.274-0.835), the proportion of patients with a more severe 
acute rejection was similar. A PBT decreased this proportion from 81% to 37.5% in 
patients without induction therapy (p=0.082) and from 76.5% to 38.9% in patients with 
induction therapy (p=0.033). 
In conclusion, PBTs were associated with less severe acute rejection episodes in 
simultaneous pancreas-kidney transplantation, even in patients treated with induction 
therapy.  




Transfusion medicine is an essential part of the history and development of organ 
transplantation. In the beginning of the solid organ transplantation era, the transfusion 
of allogeneic blood to transplanted patients was avoided, because leukocytes in the 
blood product were supposed to induce alloantibodies that are associated with 
rejection of the allograft (1). This was the case until 1973, when Opelz et al. (2) 
identified a significantly better kidney graft survival in recipients of multiple 
pretransplant allogeneic blood transfusions compared with non-transfused recipients. 
Surprisingly, it was suggested that this improved outcome was mediated by leukocytes 
of blood donor origin (3). Thus, leukocytes seem not only to activate the recipient’s 
immune system leading to alloantibody formation, but can as well suppress the 
recipient’s immune response upon transplantation. The immunological mechanism 
leading to improved graft outcome is thought to depend on multiple factors, of which 
one may be the induction of regulatory T cells in case an HLA-DR shared pretransplant 
blood transfusion is given (4).  
In the eighties, the improvement of rejection diagnosis, immunosuppressive therapy 
and overall patient care questioned the residual benefits of pretransplant blood 
transfusions (5). Nevertheless, some studies still showed a beneficial effect of 
pretransplant blood transfusions in transplanted patients who received potent 
immunosuppressive drugs (6-10), although results were not unequivocal (11). The 
detrimental effects of blood transfusion, such as the risk of transmitting infectious 
diseases and the risk of alloimmunization, also contributed to a reserved pretransplant 
transfusion policy in many transplant centers.  
At the Leiden University Medical Center, transfusion pre-treatment was continued for 
pancreas-kidney transplantation. Patients on the waiting list for simultaneous 
pancreas-kidney transplantation (SPKT) received an one HLA-DR matched, leukocyte-
containing protocolled blood transfusion (PBT) in case there was no prior exposure to 
alloantigens, e.g. by pregnancies or therapeutic blood transfusions. In this study, we 
describe the effect of such a deliberate blood transfusion in the cohort of patients who 
underwent SPKT between 1996 and 2005. During this time period modern 
immunosuppressive maintenance and induction therapy were introduced to reduce the 
incidence of acute rejection episodes (12,13). Since induction therapy may alter or even 
abolish transfusion-induced immunomodulation, we also investigated whether it 




MATERIALS AND METHODS 
 
Study population 
SPKT was performed in a single center between October 1996 and June 2005. All 
patients who underwent SPKT during this period for insulin dependent type 1 diabetes 
mellitus and end-stage renal failure were included in this study (n=118). Patients with 
previous solid organ transplants were excluded.  
Before transplantation (median 220 days, range 31-1721 days), forty-nine patients 
received one unit of non-leukocyte depleted packed red blood cells, stored less than 24 
hours. Blood donors were selected on basis of one HLA-DR match with the patient and 
a negative red cell and leukocyte cross match. Sixty-nine patients received no PBT 
because of previous therapeutical (leukocyte-depleted) transfusions or pregnancy.  
Post-transplant maintenance immunosuppressive therapy consisted of standard 
regimens of calcineurin inhibitors, purine synthesis inhibitors and corticosteroids. 
Induction therapy with polyclonal antithymocyte globulin (ATG)-Fresenius (ATGF; 
Fresenius AG, Bad Homburg, Germany) or humanized antibodies against the 
interleukin-2 receptor -chain (daclizumab) was given from 1999 to 2005. To analyze 
the impact of changing the immunosuppressive regimen over the years, we divided the 
years of transplantation in year cohorts (1996-1997, 1998-1999, 2000-2001, 2002-2003, 
and 2004-2005). 
Acute rejection episodes of the kidney (within 6 months post-transplant) were biopsy-
proven. First-line treatment of rejection was 1 g methylprednisolone for three 
consecutive days. Severe acute rejections (steroid resistant or second episodes) were 
treated with ATG-Merieux (ATGM; Thymoglobulin®; Genzyme Europe BV, Naarden, 
The Netherlands) for 10 days guided by CD3 counts in peripheral blood.  
 
Statistics 
Statistical analyses were performed using SPSS version 14.0. For comparison between 
groups, cross tables with two-tailed Fisher’s exact tests were used for nominal variables 
and nonparametric Mann Whitney-U test for scale variables. In order to identify 
independent prognostic factors for occurrence of acute rejection episodes and its 
treatment with ATGM, Cox proportional hazard regression with time to acute rejection 
and ATGM treatment as dependent variables was used. Hazard ratio’s (HR) with 95% 
confidence intervals (CI) are given. P-values less than 0.05 are considered significant.  
  




Characteristics of study population and outcome 
This study consisted of 118 patients after SPKT, of whom 49 received a PBT. 
Characteristics and clinical outcome of the study population are summarized in Table 
1. As expected, there was an imbalance in gender as females were underrepresented in 
the group of patients who received a PBT (p=0.024). Moreover, time on dialysis differed 
among both groups as patients who did not receive a PBT had a longer history of 
dialysis (p=0.041). All other relevant patient characteristics were comparable between 
the groups.  
 
Table 1: Characteristics of study population and outcomea.   
 Protocolled blood transfusion  
 No Yes p-value 
n  69 49  
Patient age (yrs) 40.4 ± 7.3 41.7 ± 7.5 0.315b
Patient sex (male/female) 33/36 34/15 0.024c
Diabetes duration (yrs) 27.4 ± 7.2 28.5 ± 6.6 0.333b
Time on dialysis (mo)d 15.9 (0-21.5) 8.9 (0.3-25.2) 0.041b
Follow up (yrs)  5.4 ± 2.4 4.7 ± 2.7 0.132b
Induction therapy (yes/no) 43/26 37/12 0.163c
PRA highest (%)d 4.0 (0-5.0) 4.0 (4.0-5.0) 0.216b
PRA recent (%)d 0 (0-4.0) 0 (0-4.0) 0.659b
HLA-A mismatch patient-organ donor 1.4 ± 0.7 1.4 ± 0.6 0.535b
HLA-B mismatch patient-organ donor 1.7 ± 0.5 1.6 ± 0.6 0.268b
HLA-DR mismatch patient-organ donor 1.4 ± 0.6 1.4 ± 0.6 0.508b
Organ donor age (yrs) 32.5 ± 12.5 30.6 ± 12.1 0.402b
Organ donor sex (male/female) 33/36 20/29 0.461c
Acute rejection at 6 mo (n (%)) 38 (55.1)  26 (53.1)  0.853c
Severe acute rejection requiring ATGM (n (%))  30 (78.9)  10 (38.5) 0.002c
Patient survival at 6/12/60 mo (%)  95.7/95.7/92.8 95.9/93.9/87.8 0.526c
Kidney graft survivale at 6/12/60 mo (%) 97.1/97.1/94.2 100/100/100 0.426c
Pancreas graft survivale at 6/12/60 mo (%) 88.4/87/81.2 95.9/93.9/93.9 0.111c
a Data are presented as mean ± SD, unless noted 
b Mann-Whitney U test 
c Fisher exact test 
d Data are presented as median (25%-75% IQR) 
e Death-censored survival 
 
 
With respect to transplantation outcome, no differences in acute rejection episodes 
were found between patients without and with a PBT (55.1% versus 53.1% respectively; 
p=0.853). If rejection occurred, 78.9% (30 out of 38) of patients without a PBT 
experienced a more severe acute rejection requiring ATGM in comparison with 38.5% 
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(10 out of 26) of patients who did receive a PBT (p=0.002). Graft and patient survival, 
with a median follow-up of 5.1 years, were not different in both groups.  
 
Induction therapy decreases the occurrence of acute rejection episodes 
In order to identify prognostic factors for occurrence of acute rejection episodes, 
univariate and multivariate analyses were applied (Table 2). In univariate analysis, 
induction therapy significantly reduced the number of patients with acute rejection 
episodes (hazard ratio (HR): 0.371, 95% CI: 0.226-0.610, p<0.001). This is graphically 
represented in Figure 1A. Moreover, patients with more recently transplanted organs 
(year cohorts: 1996-1997, 1998-1999, 2000-2001, 2002-2003, 2004-2005) developed fewer 
acute rejection episodes (HR: 0.684, 95% CI: 0.560-0.837, p<0.001) (Table 2A).  
Cox proportional hazard regression (adjusted for patient age, patient sex, diabetes 
duration, time on dialysis, PBT, organ donor age and HLA-DR mismatch between 
patient and organ donor) identified both induction therapy and year of transplantation 
as independent prognostic factors for a lower incidence of acute rejection episodes 
(induction therapy HR: 0.478, 95% CI: 0.274-0.835, p=0.010; year of transplantation HR: 
0.784, 95% CI: 0.637-0.965, p=0.022) (Table 2B).  
 
Table 2: Effect of different characteristics on occurrence of acute rejection episodes in univariate (A) 
and multivariate (B) analysis. 
A
Characteristic Hazard ratio 95% CI p-value 
Patient age 0.977 0.945-1.010 0.173 
Patient sex (male vs female) 0.848 0.517-1.390 0.513 
Diabetes duration 0.983 0.948-1.018 0.333 
Time on dialysis 0.999 0.984-1.016 0.949 
PBT 0.808 0.490-1.331 0.402 
Induction therapy 0.371 0.226-0.610 <0.001 
Organ donor age 1.006 0.986-1.027 0.552 
Organ donor sex (male vs female) 0.908 0.554-1.488 0.701 
Year of transplantation 0.684 0.560-0.837 <0.001 
HLA-A mismatch patient-organ donor 1.035 0.711-1.507 0.855 
HLA-B mismatch patient-organ donor 1.629 0.989-2.680 0.055 
HLA-DR mismatch patient-organ donor 1.227 0.809-1.860 0.336 
B
Characteristic Hazard ratio 95% CI p-value 
Induction therapy 0.478 0.274-0.835 0.010 
Year of transplantation 0.784 0.637-0.965 0.022 
Multivariate analysis: adjusted for patient age, patient sex, diabetes duration, time on dialysis, PBT, organ donor age 
and HLA-DR mismatch patient-organ donor  
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Protocolled blood transfusions are associated with less severe acute rejections   
To identify prognostic factors for occurrence of more severe acute rejections that 
required ATGM treatment (Table 3), only patients who experienced an acute rejection 
episode (n=64) were selected. In univariate analysis an association was found between 
incidence of more severe acute rejections and patient age, diabetes duration, PBT and 
year of transplantation. Older patients and patients with a longer history of diabetes 
had fewer severe acute rejection episodes (HR: 0.934, 95% CI: 0.890-0.980, p=0.006 and 
HR: 0.948, 95% CI: 0.902-0.996, p=0.035 respectively). Patients who received a PBT were 
less frequently treated with ATGM (HR: 0.343, 95% CI: 0.167-0.704, p=0.004), as was the 
same for patients who were transplanted more recently (HR: 0.738, 95% CI: 0.584-0.933, 
p=0.011) (Table 3A).   
After adjustment for patient age, patient sex, diabetes duration, time on dialysis, 
induction therapy, organ donor age and HLA-DR mismatch between patient and organ 
donor in a multivariate model, PBT and a more recent year of transplantation remained 
as independent prognostic factors for decreasing the risk of developing a more severe 
acute rejection requiring ATGM (PBT HR: 0.385, 95% CI: 0.186-0.796, p=0.010; year of 
transplantation HR: 0.774, 95% CI: 0.610-0.983, p=0.036) (Table 3B).   
 
Table 3: Effect of different characteristics on occurrence of more severe acute rejections in univariate 
(A) and multivariate (B) analysis.  
A
Characteristic Hazard ratio 95% CI p-value 
Patient age 0.934 0.890-0.980 0.006 
Patient sex (male vs female) 0.814 0.437-1.514 0.515 
Diabetes duration 0.948 0.902-0.996 0.035 
Time on dialysis 1.010 0.988-1.032 0.373 
PBT 0.343 0.167-0.704 0.004 
Induction therapy 0.760 0.408-1.415 0.386 
Organ donor age 0.998 0.973-1.023 0.874 
Organ donor sex (male vs female) 0.917 0.490-1.718 0.787 
Year of transplantation 0.738 0.584-0.933 0.011 
HLA-A mismatch patient-organ donor 0.971 0.604-1.562 0.904 
HLA-B mismatch patient-organ donor 0.838 0.421-1.670 0.616 
HLA-DR mismatch patient-organ donor 1.319 0.791-2.201 0.288 
B
Characteristic Hazard ratio 95% CI p-value 
PBT 0.385 0.186-0.796 0.010 
Year of transplantation 0.774 0.610-0.983 0.036 
Multivariate analysis: adjusted for patient age, patient sex, diabetes duration, time on dialysis, induction therapy, organ 


































Figure 1: Graphic representation of occurrence of acute rejection episodes (A) and more severe acute rejections (B 
and C) of SPKT patients. Graph A shows that patients treated with induction therapy had a lower incidence of acute 
rejection episodes (HR: 0.371, 95% CI: 0.226-0.610, p<0.001). For analysis of occurrence of more severe acute 
rejections, only patients were selected with first acute rejection episodes (n=64). A PBT reduced the incidence of 
severe acute rejections in patients without induction therapy (graph B; HR: 0.334, 95% CI: 0.097-1.151, p=0.082) as 
well as in patients with induction therapy (graph C; HR: 0.366, 95% CI: 0.145-0.923, p=0.033). Statistics: Cox 
proportional hazard regression.  
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Beneficial effect of protocolled blood transfusion is retained after induction therapy 
Since patients were conditioned with induction therapy from 1999 onwards, the effect 
of a PBT could be evaluated in the groups with and without induction therapy. Patients 
not treated with induction therapy, had a severe acute rejection episode in 81% (17 out 
of 21) of the cases when no PBT was given, while a severe acute rejection occurred in 3 
out of 8 patients (37.5%) after receiving a PBT (HR: 0.334, 95% CI: 0.097-1.151, p=0.082) 
(Figure 1B). Patients who did receive induction therapy and no PBT needed ATGM 
rejection treatment in 13 out of 17 cases (76.5%), in comparison with 38.9% (7 out of 18) 
of patients who did receive a PBT (HR: 0.366, 95% CI: 0.145-0.923, p=0.033) (Figure 1C). 
In the latter group, two patients died within 6 months post-transplant and were 
excluded for evaluation of severe acute rejection occurrence.   
Five year graft and patient survival were not different in multivariate analysis between 
patients without and with a PBT irrespective of induction therapy (data not shown).   
 
DISCUSSION  
This retrospective study shows a beneficial effect of PBTs in combined pancreas-kidney 
transplantation. We evaluated the effect of a one HLA-DR matched PBT on clinical 
outcome after SPKT. Multivariate analysis depicted a PBT as the major prognostic 
factor for a lower occurrence of severe acute kidney graft rejections that had to be 
treated with ATGM. This effect of PBTs was present irrespective of the use of induction 
treatment. Induction treatment itself significantly reduced the incidence of acute 
rejection episodes, but not the proportion of severe, refractory rejections.  
After SPKT, acute rejection of the kidney graft occurs in a substantial number of 
patients. In our patient population an average of 54% experienced an acute rejection 
episode of the kidney within the first 6 months after transplantation. Acute rejections of 
the pancreas graft also occur, but are usually less severe and preceded by kidney graft 
rejection. From 1999 onwards induction therapy was introduced in our transplantation 
program in order to reduce acute rejections. Its effectiveness has been shown in several 
studies (12-15) and is confirmed in our patients using ATGF or daclizumab induction 
therapy. Besides the use of ATGF as induction treatment to reduce acute rejections, 
ATG is often used to treat severe rejection episodes that are in most cases steroid 
resistant (16-18). Different ATG products, derived from two different sources: a rabbit 
anti-Jurkat cell line (ATGF) and a rabbit anti-human thymocyte line (ATGM), are used 
for induction therapy and for second line treatment of acute rejections respectively to 
circumvent serum sickness. The potent immunosuppressive effects of ATG products 
are associated with prolonged immunodeficiency and increased risk of infections and 
death (19-23). If a PBT would be able to reduce the use of ATGM for severe acute 
rejections, this may reduce the potential risks for these complications.  
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Univariate and multivariate analysis revealed that a PBT did not affect the occurrence 
of acute rejection episodes. This is in agreement with two other studies. A randomised 
study performed by the group of Hiesse et al. found no beneficial effect of a HLA-DR 
matched PBT on acute rejection episodes in kidney transplant patients (11). In an 
observational study, Stratta et al. found no significant effect of a random pretransplant 
transfusion on occurrence of acute rejection episodes after SPKT (24). However, when 
we looked into more severe acute rejections that required ATGM treatment, we found a 
beneficial role of a PBT. This effect was present independently of the year of 
transplantation, despite the increasing use of more potent immunosuppressive drugs 
that reduce the incidence of rejection.  
Daclizumab and ATGF act by a different mechanism, however their common goal is to 
reduce the number of activated recipient T cells able to attack the donor organ. 
Although the immune mechanism exerting the presumed beneficial role of PBTs in 
clinical transplantation is still not known, the advantage of HLA-DR compatibility 
between blood donor and recipient was proposed in several studies (4,6). It is 
hypothesized that CD4+ recipient T cells recognizing an allogeneic peptide in the 
context of the shared HLA-DR antigen after PBT, can act as regulatory T cells (Tregs) 
and down-regulate an immune response to the graft (25-27). It has been proposed that 
such recipient Tregs may be inactivated by therapy with either ATGF or daclizumab. 
Our observation that a clinically relevant beneficial effect of PBTs also exists in patients 
who received induction therapy (p=0.033) suggests that the beneficial PBT effect is not 
abolished after induction therapy. Moreover, recent studies emphasize that induction 
therapy may save the Treg pool and may even be involved in induction of Tregs (28-
30).  
A major flaw in our study is the difference in immunologic risk profile between 
patients with and without a PBT, because the inclusion criteria for PBT select 
predominantly untransfused males. With respect to alloimmunization as detected by 
antibody formation, both groups were comparable and showed a low PRA (median: 
4%). However, PBT excluded patients may have, by pregnancy and therapeutic 
transfusions induced, memory cells without detectable alloantibodies, which may play 
a role causing more aggressive rejections. On the other hand, residual leukocytes in a 
therapeutic blood transfusion and trafficking of fetal cells into the maternal circulation 
during pregnancy may have a similar beneficial affect as a PBT.  
The retrospective nature of our study allowed us to correct only for known risk factors 
in multivariate analyses, whereas unknown confounders for rejection may still be 
present. The indication for a PBT did not change during the study interval. Before 
application of induction treatment in 1999, 32% of the 38 patients received a PBT as 
compared to 46% of the 80 patients treated after 1999. This difference is not significant 
but may reflect a tendency for more restrictive therapeutic transfusion triggers over 
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time, resulting in an increase of eligible patients for a PBT after 1999. The causal benefit 
of a PBT can only be demonstrated in a prospective randomised study. Only three 
prospective, randomized controlled trials have been performed investigating the blood 
transfusion effect in solid organ transplantation on graft rejection with unequivocal 
conclusions (10,31), of which one study showing no effect has taken into account the 
presence of HLA-DR sharing leukocytes in the blood product (11).  
In conclusion, a PBT was associated with a reduction in severe acute rejection episodes 
in patients after SPKT, irrespective of the use of potent immunosuppressive drugs. 
While induction therapy decreased the occurrence of acute rejections, PBTs seemed to 
suppress the immune response after transplantation thereby preventing the additional 
need for ATGM. Only a prospective, randomized controlled study can strengthen our 
data and investigate a causal role of a PBT in present times of modern 
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Pretransplant blood transfusions have shown to improve organ allograft survival. 
However, the immunological mechanism leading to this beneficial effect in clinical 
transplantation is still not clear. The observation that blood transfusions sharing an 
HLA-DR antigen with the recipient are more effective than HLA mismatched 
transfusions, has led to the hypothesis that CD4+ regulatory T (Treg) cells that 
recognize a foreign peptide in the context of the shared HLA-DR molecule play an 
important role in down-regulation of the immune response toward the graft. Available 
experimental evidence supports this hypothesis. Furthermore, these CD4+ Treg cells are 
able to modulate antigen-presenting cells, which in their turn will induce Treg cells. As 
long as clinical transplantation tolerance by blood transfusions is not a reality, further 
studies on the mechanisms of the beneficial effect of pretransplant allogeneic blood 
transfusions are needed to obtain an effective protocol for the induction of clinically 
relevant Treg cells. 
 




Blood transfusions can induce seemingly opposite immunological effects in the 
recipient. They can lead either to immunization or to induction of immunological 
tolerance. Immunization is reflected by appearance of alloantibodies (1,2), of which 
HLA antibodies can cause febrile transfusion reactions and hyperacute rejection of 
mismatched organ transplants. 
Clinical phenomena that have been associated with the induction of 
immunosuppression by blood transfusion include increased susceptibility for 
postoperative infections (3), whereas immunologic tolerance induced by blood 
transfusions is held responsible for successful pregnancies in women with recurrent 
abortions and reduction of rejection of solid organ transplants (4,5).  
In this review, we would like to restrict ourselves to the alloimmune response against 
the HLA alloantigens and the relevance of pretransplant blood transfusions in clinical 
transplantation. We will show that the degree of HLA matching between blood donor 
and recipient is a determining factor for the final immunologic effect of a blood 
transfusion and that the induction of CD4+ regulatory T (Treg) cells may be essential for 
the induction of the immunomodulatory effect of pretransplant blood transfusions. 
 
Historical and clinical data of pretransplant blood transfusions 
In 1963, Medawar (6) reported the reduction of the immunologic rejection of skin 
homografts in mice after the infusion of antigenic tissue extracts. In 1964, Halasz et al. 
(7) reported that dogs pre-treated with blood from the donor had a prolonged survival 
of a renal allograft. A beneficial effect of blood transfusions on graft outcome was also 
suggested in man (8,9) and was demonstrated in mice (10), rats (11-13) and primates 
(14).  In 1973, Opelz et al. (15) identified, in a multivariate analysis of the outcome of 
cadaver kidney graft transplantation, a significant enhancement of kidney graft 
survival in recipients of multiple pretransplant allogeneic blood transfusions compared 
with nontransfused recipients. Subsequently, Persijn et al. (16) demonstrated that this 
beneficial effect only occurred when the blood transfusion was not leukocyte depleted 
and that even patients who received only one single blood transfusion had a kidney 
graft survival of 80% after 8 months, whereas transplanted patients who received one 
or three leukocyte-free blood transfusion(s) had a graft survival of only 25%. Thus, 
apparently, leukocytes are important for the induction of the tolerating effect of 
allogeneic blood transfusions.  
The appearance of transfusion-transmitted HIV at approximately the same time as the 
improvement of graft survival by advanced patient care, better histocompatibility 
matching, and the introduction of cyclosporine questioned the need for a possible role 
for pretransplantation allogeneic blood transfusions in the 1980s. Indeed, in some 
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observational studies, pretransplant blood transfusions did not lead to better graft 
survival compared with that seen in nontransfused patients (17,18); but in a prospective 
randomized study, the beneficial effect of pretransplant allogeneic blood transfusions 
could still be demonstrated in patients who received very efficient immunosuppressive 
drugs (19).  
The beneficial effect of pretransplant blood transfusions is restricted not only to kidney 
transplants. Also in heart transplantation (20,21) and combined pancreas-kidney 
transplantation (Waanders et al, manuscript in preparation), pretransplant blood 
transfusions are associated with a lower risk of rejection.  
 
The need for HLA compatibility between blood donor and recipient 
The aforementioned studies from the 1980s suggested that white blood cells play an 
essential role in the induction of transplantation tolerance. In addition, retrospective 
analysis of graft survival showed that HLA-DR compatibility between patient and 
blood donor is of great importance. Lagaaij et al. (20) demonstrated that patients 
transfused with HLA-DR shared blood had better kidney graft survival compared with 
patients who received completely HLA-DR mismatched transfusions. For this effect to 
be observed, an additional requirement seems to be HLA class II disparity on the other 
haplotype (22).  
A similar differential impact of HLA compatibility was observed with respect to the 
humoral alloimmune response to allogeneic blood transfusions. The incidence of HLA 
alloantibody formation was significantly higher after completely HLA-DR mismatched 
transfusions compared with (partly) HLA-DR shared transfusions. Furthermore, if 
antibodies are formed, HLA-DR shared allogeneic transfusions are associated with the 
production of IgM alloantibodies, whereas HLA-DR mismatched transfusions lead to 
IgG alloantibodies. Several other groups confirmed the beneficial effect of HLA-DR 
sharing between blood donor and recipient and observed fewer post transplant 
rejection episodes in renal and cardiac allograft recipients and improved patient 
survival after kidney transplantation (21,23-25). However, Christiaans et al. (26) did not 
observe differences in development of alloantibodies or graft survival between 
recipients of an HLA-DR matched and HLA-DR nonmatched transfusion.  
In vitro monitoring of T cell alloreactivity of patients after pretransplant blood 
transfusions has led to controversial observations. A differential influence of HLA-DR 
shared versus mismatched allogeneic transfusions on induction of donor-specific 
cytotoxic T lymphocytes (CTLs) was described. HLA-DR shared transfusion led to a 
marked reduction of the number of CTLs, whereas HLA-DR mismatched transfusions 
increased the CTL precursor frequency (27). This finding was confirmed in a mouse 
model in which semi-allogeneic blood transfusions resulted in less sensitization 
(cellular and humoral) than fully allogeneic transfusions (28). Moreover, it was found 
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that an HLA mismatched allogeneic blood transfusion led to high-affinity CTLs against 
immunogenic class I mismatched antigens (29). However, other studies showed that 
both HLA-DR shared and mismatched transfusions activate the alloreactive T cell 
compartment (30,31). The discrepant effect on T cell responses may be explained by a 
different composition of pretransplant allogeneic blood transfusions, differences in 
storage time of the blood, and in the time interval between transfusion and the in vitro 
assays.  
In summary, although clinical data such as HLA alloantibody formation and graft 
survival suggest that (partly) HLA-DR shared blood transfusions lead to down-
regulation of the alloimmune response in the recipient, the effect on the T cell 
compartment is less clear. 
 
Mechanisms of transfusion-induced immunomodulation 
Although the effect of a pretransplant allogeneic blood transfusion has been recognized 
for some decades, there are hardly any data available with respect to the immunologic 
mechanism leading to the beneficial effect in clinical transplantation. The observation 
that the beneficial effect of pretransplant allogeneic blood transfusions was not seen in 
patients who received antithymocyte globulin as induction therapy, suggests that T 
cells may play an important role (32).  
Experimental data in animals support several mechanisms, including clonal deletion, 
anergy, anti-idiotypic antibodies, veto cells, and the induction of Treg cells.  
Also in man, several explanations for the immunomodulatory effect of blood 
transfusions have been suggested. For an efficient induction of an alloimmune response 
it is essential that the antigen-presenting cells (APCs) in the blood carry both allogeneic 
HLA antigens (signal 1) and costimulatory molecules (signal 2). Only if both signals are 
present will this lead to activation of alloreactive T cells. After storage of blood, there is 
a lower expression of costimulatory molecules on the donor leukocytes. Subsequent 
transfusion of these impaired APCs will induce anergy rather than activation of the 
donor specific T cells in the recipient (33). It has also been shown that transfusions may 
lead to long-term (micro)chimerism leading to 2-way tolerance (34). Moreover, soluble 
HLA, Fas and other molecules accumulate in donor blood and can modulate the 
alloimmune response of the recipient (35). Binding of the soluble molecules to the 
alloreactive T cells will lead to apoptosis rather than to activation. However, these 
putative mechanisms do not explain why HLA-DR sharing between blood donor and 




In our opinion, the shared HLA-DR antigens may be the clue to the mechanism 
involved in the beneficial effect of pretransplant allogeneic blood transfusions. But how 
can a shared HLA-DR antigen affect the recipient's immune system? There are 2 
distinct pathways of allorecognition by T cells. In direct allorecognition, T cells 
recognize intact allogeneic HLA molecules on the surface of donor APCs in the graft 
(Figure 1A). Indirect allorecognition is based on T cell recognition of an allogeneic 
peptide in the context of recipient HLA class II molecules after they have been 
processed and presented by recipient APCs (Figure 1B), which is similar to the T cell 
response to bacterial or viral antigens. With respect to the immunomodulating effect of 
HLA-DR shared blood transfusions, it is essential that the immune system of the 
recipient recognizes the shared HLA-DR antigen, which is only possible if it contains a 
foreign peptide. As the shared HLA-DR antigen is present on donor APCs, it is indeed 
likely that the shared HLA-DR antigen contains many foreign allopeptides. These 
allopeptides may be derived from mismatched HLA class I molecules, minor 
transplantation antigens or any polymorphic protein present in the donor and not in 
the recipient (36). Recipient CD4+ T cells that recognize this foreign peptide in the 





Figure 1: Direct and indirect pathways of T cell allorecognition. (A) In direct allorecognition, T cells directly recognize 
an allogeneic HLA molecule on the surface of donor antigen presenting cells (APCs) in the graft. (B) In indirect 
allorecognition, T cells recognize an allogeneic peptide in the context of recipient HLA class II molecules, after 
processing and presentation by recipient APCs.  
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Figure 2: Allorecognition after an HLA-DR matched blood transfusion. T cells of the recipient recognize a donor-
derived peptide in the context of a shared HLA class II molecule, leading to T cells with a similar specificity as the ones 
described in Figure 1B. 
 
 
The next question is, how can these CD4+ T cells mediate down-regulation of the 
alloimmune response to a donor kidney or heart from a complete different individual 
than the blood transfusion donor? We hypothesize that this can be possible if the organ 
donor shares at least 1 of the allopeptides with the blood transfusion donor. When 
recipient T cells get activated by the graft, they start to express HLA class II molecules 
and may present an allopeptide shared between the organ donor and the blood 
transfusion donor. In this way, the same complex of allopeptide and self-HLA class II 
molecule will become available after transplantation and may serve as a specific target 
for the CD4+ T cells induced by the allogeneic blood transfusion (Figure 3). The CD4+ T 
cells which down-regulate the immune response toward the graft are presumably Treg 
cells (37,38).  
In the first 5 months after transplantation, organ donor-derived passenger APCs are 
also present (39). In case there is HLA-DR sharing with the allogeneic blood transfusion 
donor and the recipient, APCs from the graft may present the specific allopeptide-HLA 
complex. In this special case, APCs derived from the graft may also serve as a specific 
target for CD4+ Treg cells, which are induced by the blood transfusion (not shown in 
figures). However, the blood transfusion effect is independent of the HLA-DR 



















Figure 3: Proposed role of alloreactive T cells in antigen presentation after transplantation. (A) T cells of recipient 
origin may directly recognize allogeneic HLA molecules on the surface of the transplanted organ, which results in (B) 
expression of HLA class II molecules. Alloreactive T cells can pick up and present the donor-derived peptides to CD4+



















Figure 4: Proposed role of recipient DCs in antigen presentation after transplantation. After processing, organ donor-
derived peptides are presented in the context of HLA class II molecules on recipient DCs and serve as a target for 
CD4+ Treg cells induced by the blood transfusion. 
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Several months after transplantation, in all recipients, the APCs of the organ donor are 
replaced by APCs (ie, dendritic cells or DCs) of the recipient. Recipient DCs can also 
process and present organ donor-derived peptides and function as professional APCs 
(40). Recipient CD4+ T cells induced by the allogeneic blood transfusion may indirectly 
recognize organ donor-derived peptides presented by recipient DCs, which may lead 
to down-regulation of the immune response toward the graft (Figure 4). 
Besides the possibility that the CD4+ Treg cells with indirect allospecificity down-
regulate the alloimmune response to the organ donor, these CD4+ Treg cells may also 
lead to modulation of the DCs. These modulated DCs may induce non-responsiveness 
of the potential donor reactive T cells of the recipient. Modulation of DCs through 
maturation in the presence of interleukin (IL) 10, can lead to APCs which preferentially 

























Figure 5: Proposed action of IL-10 in modulating the immune response toward the graft. (A) IL-10 produced by CD4+
Treg cells facilitates the generation of modulated DCs. (B) The modulated DCs promote the differentiation of naive 
alloreactive T cells into Treg cells via IL-10. (C) In turn, the newly formed Treg cells can affect newly developing DCs 
by their IL-10 production, which may modulate immune responses toward the graft.  
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In Figure 5, it is shown that IL-10 production by the CD4+ Treg cell may facilitate the 
generation of modulated DC. In turn, the modulated DC may promote differentiation 
of naive alloreactive T cells into Treg cells (by production of IL-10 or reduced 
stimulation or costimulation). These Treg cells can produce IL-10 again and may affect 
the function of newly developing DCs. Such an inhibitory feedback loop between 
tolerogenic DCs and Treg cells has also been described in the transplantation tolerance 
seen in a mouse model (43). 
The CD4+ Treg cells in this hypothesis are probably different from the naturally 
occurring Treg cells (CD4+CD25+), which are involved in the prevention of autoimmune 
reactions and the maintenance of peripheral tolerance to self-antigens (44). Blood 
transfusion-induced CD4+ Treg cells are only found after confrontation with the 
allogeneic blood transfusion donor APCs carrying the combination of shared HLA class 
II and a foreign peptide. Whether these cells are expanded from the naturally occurring 
Treg cells or are newly induced Treg cells remains to be established.  
 
Experimental and clinical evidence for the hypothesis 
To find support for this hypothesis, we tested whether CD4+ T cells recognizing an 
allopeptide in the context of self-HLA class II do have regulatory properties. We could 
generate in vitro CD4+CD25+ T cell clones which down-regulate the alloreactive 
immune response of autologous cytotoxic T cells, provided the proper peptide was 
present (45). These CD4+ T cells lyse autologous activated (HLA class II positive) T cells 
in the presence of a specific peptide, which is supportive of the mechanism described in 
Figure 3. Besides a putative regulatory function based on lysis of target cells, these 
CD4+CD25+ T cells produce considerable amounts of IL-10 when confronted with the 
proper peptide HLA-DR complex. IL-10 is typically one of the cytokines that is 
produced by Treg cells and not by ordinary type 1 T helper cells (involved in evoking 
cellular immune responses). The large quantities of IL-10 produced by these CD4+ Treg 
cells make them particularly suitable for affecting the function of APCs, as shown in 
Figure 5. 
To substantiate these in vitro data with clinical observations, we studied the CD4+ T 
cells of renal transplant recipients who received HLA-DR shared allogeneic blood 
transfusions. The reactivity of recipient CD4+ T cells against the transfusion donor in 
patients who received an HLA–DR shared blood transfusion was compared with the 
reactivity after an HLA-DR mismatched blood transfusion. An HLA-DR mismatched 
blood transfusion led to increased donor-specific interferon  (IFN ) production 
without detectable IL-10 production. In contrast, HLA-DR matched transfusions 
induced significantly less donor-specific IFN  production, whereas in a proportion of 
the patients, increased IL-10 production was observed (46). These data are in 
concordance with the assumption that HLA-DR mismatched allogeneic blood 
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transfusions are associated with immunization (IFN  production is a parameter for 
type 1 T helper cell reactivity), whereas HLA-DR shared transfusions are associated 
with the induction of tolerance (IL-10 production is a marker for Treg cells). However, 
these observations reflect the immune response to the allogeneic blood transfusions. 
The impact of HLA-DR shared blood transfusions on the alloimmune response toward 
the transplanted organ remains to be clarified. 
Recently, we have started to analyze the organ donor-specific T cell repertoire of 
patients with well-functioning kidney grafts, who had received an HLA-DR shared 
pretransplant blood transfusion. Thus far, these patients were found to have a low 
organ donor-specific CTL frequency after transplantation. Further studies in vitro 
showed that this low donor-specific CTL precursor (CTLp) frequency is not due to the 
absence of donor-specific CTLs, but rather to the effect of CD4+ T cells which prevent 
the reactivity of donor-specific CD8+ CTLs. When the CD4+ T cells were removed from 
the leukocyte population, a significant organ donor-specific CTL response could be 
observed. This phenomenon was donor-specific as no significant effect was observed 




Both clinical studies and in vitro models suggest that allogeneic blood transfusions may 
lead to down-regulation of the immune response against allogeneic HLA antigens 
presented by transplanted organs. Some of these effects are dependent on the 
transfusion dose and the length of storage of allogeneic blood. We further showed that 
a single transfusion containing viable leucocytes can mediate allograft tolerance, 
provided that HLA-DR sharing is present between the blood donor and the recipient. 
We have indirect evidence that this down-regulation of alloreactive cells is the result of 
the induction of CD4+ Treg cells that recognize an allopeptide in the context of a self-
HLA class II molecule. 
The fact that an HLA-DR antigen or HLA haplotype should be shared to induce a Treg 
cell that prevents a destructive alloimmune response, shows similarities with the 
situation that occurs during pregnancy. Mother and child always share at least 1 HLA 
haplotype, and allorecognition will always imply indirect recognition of an allopeptide 
in the context of self-HLA class II. Also in this case, Treg cells may be induced (47).  
This is in line with the observation that immunized patients less likely produce 
alloantibodies against maternal HLA mismatches compared to paternal HLA 
mismatches and may also explain why renal transplants mismatched for noninherited 
maternal HLA antigens have a significantly better graft survival than renal transplants 
mismatched for noninherited paternal HLA antigens (48,49). A recent study reveals 
that also in bone marrow transplant recipients, the incidence of graft vs host disease is 
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significantly lower when allorecognition involves the noninherited maternal HLA 
antigens (50). These data suggest that the induction of regulatory cells by HLA-DR 
shared APCs is not restricted to allogeneic blood transfusions but may also apply to 
fetomaternal exchange in pregnancy, in which the effect is long-lasting. Compared with 
the current immunosuppressive drugs, allogeneic blood transfusions are less toxic. 
However, as long as allogeneic blood transfusion-induced clinical transplantation 
tolerance does not become a reality, further studies on the mechanisms of the 
immunomodulatory effect of allogeneic blood transfusions are needed before an 
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Monitoring of T cells involved in an alloimmune response requires the presence of in 
vitro assays which can detect T cells with direct as well as indirect allospecificity. While 
generally accepted assays exist to measure helper and cytotoxic T cells involved in 
direct allorecognition, consensus about an assay for monitoring indirect T cell 
responses in clinical transplantation is lacking. Many studies claim a relationship 
between the reactivity of T cells with indirect allospecificity and allograft rejection, but 
different approaches are used and often essential controls are lacking. In this review, 
the disadvantages and pitfalls of the different approaches used so far are discussed and 
supported by our own in vitro assays. We conclude that an international workshop is 
necessary to establish and validate a uniform, robust and reliable assay for the 
monitoring of transplant recipients and to study the actual role of indirect 
allorecognition in acute and chronic rejection.  
 




Transplantation, blood transfusion or pregnancy may result in activation of alloreactive 
T cells leading to rejection, graft versus host disease and/or induction of IgG 
alloantibodies. These alloreactive T lymphocytes recognize non-self antigens, mostly 
derived from the highly polymorphic major histocompatibility complex (MHC) on 
allogeneic cells or tissue. The way by which T lymphocytes recognize alloantigens has 
been the focus of many studies and can occur by two distinct, not mutually exclusive 
pathways: the direct and indirect pathway. 
Direct allorecognition refers to the recognition of intact allo-MHC molecules expressed 
on the surface of donor antigen-presenting cells APCs). Allorecognition in this way 
results in a vigorous immune response, due to the high precursor frequency of T cells 
involved in this pathway (1). Two hypotheses have been proposed for this T cell 
activation, referred to as the ‘high determinant density model’ and the ‘multiple binary 
complex model’. In the high determinant density model it is presumed that every MHC 
molecule on the cell surface, irrespective of the bound peptide, can serve as a ligand for 
host alloreactive T cells. The high antigen density may thus account for the vigorous 
immune response. In the multiple binary complex model, the peptide bound in the 
groove of the allo-MHC molecule is the decisive entity. Here each peptide-allo-MHC 
complex is recognized by a unique host alloreactive T cell, also leading to a strong 
immune response. It is obvious that direct allorecognition only occurs after transfer of 
tissues or cells between genetically different individuals. In contrast, the mechanism of 
indirect allorecognition is basically not different from MHC restricted recognition of 
virally encoded antigens.   
Indirect allorecognition is the stimulation of recipient T lymphocytes by processed 
donor antigens presented as peptides in the context of self-MHC. Evidence for this 
alternative pathway of T cell allorecognition came from observations that graft rejection 
still occurred in the absence of immunogenic donor-derived passenger cells in the graft 
(2). Alloantigens shed from the graft are internalized and processed in the same way as 
exogenous antigens and presented by recipient APCs as peptides in self-MHC class II 
molecules to CD4+ T cells. The frequency of T cells with indirect recognition is two 
orders of magnitude lower than T cells directly recognizing alloantigens, while the 
maximal response in the indirect pathway peaks later (3).   
To gain more insight into these alloimmune responses and eventually control them, it is 
essential to develop reliable in vitro assays to monitor the magnitude and specificity of 
a T cell alloimmune response. Although assays such as the mixed lymphocyte culture 
(MLC), the cytotoxic T cell precursor (CTLp) assays and HLA antibody screening have 
shown to be useful for monitoring transplant recipients, we question in this review the 
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reliability of assays used so far for the detection of indirect allorecognition in clinical 
transplantation.  
 
Allorecognition and allograft rejection  
Both the direct and indirect pathway of allorecognition can lead to graft rejection. 
Direct recognition of alloantigens predominates in the first weeks to months after 
transplantation and is generated by donor derived antigen presenting cells bearing 
allogeneic MHC class II molecules. CD4+ T cells with exclusively direct allospecificity 
can mediate allograft rejection (4).   
With elapsing time after transplantation, donor antigen presenting cells fade away and 
the indirect pathway becomes more important. Evidence that the indirect pathway is 
sufficient to mediate graft rejection was given by Auchincloss et al. (5), who used  MHC 
class II deficient mice as donors in a skin allograft model. Indirect allorecognition of 
donor MHC class I antigens by host CD4  T cells could initiate rapid skin rejection. 
Moreover, allospecific CD4  T cells induced by the indirect pathway were involved in 
the generation of cytotoxic T cells against donor MHC class I and the induction of IgG 
alloantibody production (5,6). The availability of knockout mice and depletion of 
specific cell subsets enabled the study of individual cell types involved in indirect 
allorecognition. Combined with results from other experimental studies (2,7-13), this 
provides circumstantial evidence that T cells exclusively activated by the indirect 
pathway are able to mediate acute and chronic allograft rejection.  
Many clinical studies in humans support the notion that an increased frequency or 
reactivity of T cells with indirect anti-donor allospecificity is associated with chronic 
graft dysfunction or rejection.    
 
Indirect allorecognition and transplantation tolerance 
Indirect allorecognition can occur throughout the lifetime of a graft, since recipient 
APCs continuously migrate through the graft and encounter donor-derived peptides. 
Graft rejection can be caused by indirect allorecognition. On the other hand, a 
protective role of T cells with indirect allospecificity is also likely, as the presence of 
regulatory T cells with indirect allospecificity is associated with transplantation 
tolerance. Immunological tolerance involves central and peripheral mechanisms (14). 
An example of the role of indirect allorecognition in inducing a state of central 
tolerance, is the prolongation of graft survival after intrathymically administration of 
donor MHC peptides in animals (15,16). In the periphery, tolerance can be achieved by 
various mechanisms, including deletion and regulation of effector cells. Several studies 
described a state of peripheral tolerance caused by indirect allorecognition in presence 
of suboptimal stimulation (17-19), negative feedback (20) or regulation (21-24). It is also 
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believed that the beneficial effect of pre-transplant blood transfusions (25-28) is 
mediated by regulatory T cells with indirect allospecificity (29,30).  
Considering the central role of indirect recognition in graft rejection and tolerance, the 
availability of a reliable in vitro assay for monitoring indirect allorecognition is crucial.   
 
In vitro assays to monitor indirect allorecognition  
The studies that have established key factors for measuring indirect allorecognition in 
vitro are listed in Table 1. They show that in vitro allogeneic T cell responses require the 
presence of APCs, and that CD4+ cells recognize an allogeneic peptide in the context of 
a self-HLA class II molecule (31,32). T cells described to respond against allogeneic 
peptides via the indirect pathway recognized synthetic HLA peptides, as well as 
endogenous peptides (33). Moreover, autologous DCs pulsed with cellular fragments 
were able to trigger T cells with indirect allospecificity (34,35). Dominant epitopes on 
common HLA molecules were not limited to the hypervariable region of the HLA 
molecule, but could also be derived from the 3 and the transmembrane domains (36). 
Quantitative analysis showed that T cells with indirect allospecificity have a 
significantly lower frequency than cells involved in the direct allorecognition pathway 
(3) and could react by both proliferation and cytolysis (37).  
As chronic allograft rejection is thought to be mediated mainly by recipient T cells with 
indirect allospecificity, most in vitro assays aiming to detect indirect allorecognition 
have been performed after solid organ transplantation. As depicted in Table 2, recipient 
T cell reactivity to donor-like or donor-derived antigens was associated with acute as 
well as chronic rejection in numerous studies, except for some (38-43). However, in the 
following sections it will become evident that test conditions vary considerably among 
studies, while often essential controls are lacking. The different problems will be 
discussed, supported by our own in vitro experiments in order to underline the need to 
develop a robust and reproducible test system.  
 
Source of alloantigen  
Indirect allorecognition refers to the recognition of a foreign peptide in the context of a 
HLA class II molecule on self APCs by recipient CD4+ cells. The shedding of soluble 
HLA molecules during homeostasis or attack on graft tissue during inflammatory 
processes or other pathological conditions in vivo, will lead to presence of allogeneic 
cells or cellular fragments for presentation to the recipient’s immune system. They may 
end up in APCs, transported to the lymph nodes and presented to recipient T cells via 
the indirect pathway. The strength of this type of alloimmune response is dependent on 
the amount and source of antigen as well as on the strength and duration of the 
interaction between recipient APC and T cell. To ensure proper investigation of indirect 
alloimmune responses, the selection of alloantigens is crucial. An alloantigen can be 
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derived from any polymorphic protein present in the donor and not in the recipient, 
but in the transplantation setting donor HLA molecules, which can be presented via the 
direct and indirect way, account for the vigorous alloimmune responses. As alloantigen 
source, one can use donor cells or cellular fragments with the advantage that all 
possible alloantigens are available for indirect presentation. Alternatively, peptides 
derived from specific alloantigens can be generated synthetically for use in in vitro 
assays. The advantages and disadvantages of different sources of alloantigens will be 
discussed in more detail. 
 
Allogeneic cells depleted of APCs 
Theoretically, depletion of allogeneic APCs will prevent the response of recipient CD4+ 
T cells towards foreign HLA class II molecules, referred to as the direct way of 
allorecognition. As shown in Table 2A, the stimulation of recipient CD4+ T cells with 
APC-depleted allogeneic peripheral blood mononuclear cells (PBMCs) correlated with 
acute rejection in two studies (44,45), whereas other studies found no correlation 
between indirect allorecognition and acute allograft rejection (39,41,46). However, it 
cannot be ruled out that direct allorecognition still interferes in the immune reaction as 
small numbers of residual donor APCs may remain present. Therefore, the use of 
cellular fragments lacking intact HLA molecules seems a more safe way of alloantigen 
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Cellular fragments  
A big advantage of the use of fragments derived from cells of the specific donor is that 
theoretically the full repertoire of alloantigens is covered. After natural processing, 
peptides derived from the HLA class I and II molecules but also from other (minor) 
transplantation antigens are presented by the recipients antigen presenting cells. A 
disadvantage is that the specificity of the alloreactive T cells is not known. Many 
different techniques have been used for the fragmentation of cells, which makes it 
difficult to compare results obtained by different studies. Nevertheless, all studies 
listed in Table 2B found a positive association between patient response to donor 
derived cellular fragments and acute or chronic allograft rejection (47-52). It should be 
noted however, that not all studies included proper negative controls such as third 
party cellular fragments.  
Fragmentation of cells or cell membranes has some pitfalls. First, without further 
analysis, the content of a suspension after fragmentation is unknown with respect to 
the size of the particles. The suspension may contain whole membrane-derived HLA 
molecules or much smaller components similar in size to the synthetic peptides used in 
other experimental designs. Few studies performed Western blot analysis or ELISA to 
demonstrate the presence of HLA molecules after fragmentation, but even then it is 
unknown whether the HLA molecules need to be intact in order to be processed and 
presented by an APC (48,51). When membrane fragments still contain intact HLA 
molecules and costimulatory molecules, these can cause allorecognition via the direct 
pathway by patient responder cells. Recipient APCs may also acquire and integrate 
intact donor-derived HLA molecules, a process called trogocytosis (53). Thus, the 
absence of cells in the preparation does not warrant absence of direct stimulation. 
Second, the concentration of relevant constituents is unknown. A wide range of cellular 
fragments was used (equivalents of 5x104-2x106 cells), compared to the final 
concentration of synthetic peptides (10-20 g/ml per synthetic peptide) used in most 
studies. The concentration of a relevant peptide in a fragmented cell preparation is not 
known and may be much lower compared to the concentrations usually applied for 
synthetic peptides.  
The fact that different techniques exist to fragment cells as a source of donor derived 
antigens, underscores the lack of consensus on a robust and reliable test system. To 
further illustrate this, we tested the reactivity of two different CD4+ T cell clones against 
APCs with the specific restriction element after incubation with different preparations 
of the cellular fragments. Clone 4.1 recognizes a HLA-A2 peptide in the context of 
HLA-DR1. Clone 2014, derived from the ThoU6 cell line (33), recognizes a HLA-DR3 
peptide in the context of HLA-DP3. Fragmentation of HLA-A2+ and HLA-DR3+ cells 




























































































































































































































































































































































































































































































































Monitoring of indirect allorecognition 
79 
The reactivity of the clones towards natural ligand, synthetic peptides and cellular 
fragments was determined in proliferation and ELISPOT assays. The results (Figure 1) 
show that both clone 4.1 and clone 2014 recognized the natural ligand and the specific 
synthetic peptide but none of the cellular fragments. To exclude that the lack of 
proliferation of the T cell clones was due to fragmentation induced toxicity, cloned cells 
and the specific allopeptide were cocultured with (supernatants of) cellular fragments. 
Fragmentation did not result in inhibitory or toxic substances and the response to the 















Figure 1: Response of Clone 4.1 and Clone 2014 towards natural ligand, synthetic peptides and cellular fragments. 
Clone 4.1 proliferated upon stimulation with natural ligand (A2+DR1+ cell) or specific A2+ peptide (aa 101-122), but not 
upon stimulation with A2+ or A2- cellular fragments, produced by method 1, 2, 3 or 4 (n=3). Clone 2014 produced IFN  
as measured in ELISPOT upon stimulation with natural ligand (DR3+DP3+ cell) or specific DR3+ peptide (U6), but not 
upon stimulation with DR3+ or DR3- cellular fragments, produced by method 1, 2, 3 or 4 (n=2). Stimulation index=cpm 




The studies presented in Table 2C used overlapping, synthetic peptides as source of 
donor antigen (36,38,40,42,43,54-69). Both HLA class I and class II peptides 
corresponding to the donor phenotype, were used to stimulate patient cells. However, 
it can be assumed that donor-HLA class I-derived peptides are the major inducers of 
recipient T cell activation leading to chronic allograft rejection, since the expression of 
HLA class I molecules in the graft is far more abundant than that of HLA class II, 
especially after donor passenger cells bearing HLA class II molecules have 
disappeared. In that perspective it is odd that several studies aim at the detection of a T 
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cell response to synthetic HLA-DR peptides rather than to HLA class I peptides (54-
63,67).  
The advantage of using synthetic peptides is the exact knowledge of the antigen (amino 
acid length and concentration), resulting in a reproducible assay. By varying the amino 
acid length, immunodominant epitopes were identified for several HLA antigens. 
However, the indiscriminate dissection of a protein into synthetic peptides has 
disadvantages, one of them being the creation of neoepitopes. Peptides may be 
synthesized which do not occur in vivo, due to absence of natural splicing sites at 
relevant positions on the full protein. On the other hand, when working from the 
encoded sequence, one does not take into account that several posttranslational 
modification mechanisms can occur in vivo. This includes glycosylation of proteins to 
improve protein folding and stability of the peptide-HLA complex (70). By 
exogenously offering 15- to 30-mer synthetic peptides to recipient APCs, they may end 
up directly in a HLA molecule in unglycosylated form. In addition, posttranslational 
splicing of peptides has been shown to occur (71). In peptide synthesis which is purely 
based on amino acid sequence of the full protein the latter two possibilities are simply 
not considered. Apart from this and more importantly, a major flaw in many studies is 
the lack of appropriate peptide controls. To support the results of indirect T cell 
activation studies, inclusion of control peptides based on self HLA sequences, seems to 
be a logical corollary, but is rarely done.   
Half of the studies used only peptides corresponding to the donor phenotype and 
based their conclusive remarks on the response to the specific peptide. These studies 
should be considered non-conclusive as responses to synthetic peptides corresponding 
to self-HLA molecules do occur frequently. Since the adaptive antigen-specific immune 
system distinguishes self from non-self, starting with deletion of T cells in the thymus 
with a high affinity for self-antigens, it is not likely that individuals recognize a natural 
self peptide presented in the context of their own HLA class II. Figure 2 shows that 
reactivity was observed to synthetic peptides based on self HLA molecules using cells 
from a healthy non-primed individual or umbilical cord blood (UCB). The peptides 
used here probably differ from naturally processed peptides and are seen as neo-
epitopes by the autologous T cells. A logical consequence is that in some cases the 
reactivity towards synthetic allopeptides is interpreted incorrectly. This type of 
reactivity is not restricted to T cell responses to synthetic HLA peptides but also 
accounts for responses towards synthetic RhD peptides in RhD positive individuals as 
tested in our laboratory (data not shown). Our observations are in agreement with 
others. Hanvesakul et al. showed recognition of peptides with a sequence identical to 
self in patients awaiting a renal transplant, as determined in IFN  Elispot assay (36). 
Barker et al. described proliferation of naïve T cells of RhD positive individuals to 
synthetic RhD peptides and concluded that this was presumably due to 
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correspondence of the peptides to cryptic epitopes normally not presented in vivo (72). 
Two other studies also demonstrated that nonprimed T cells can respond to allogeneic 
synthetic peptides (40,42). Two possibilities arise for the response to self: absence of 
regulatory mechanisms or induction of neo-epitopes. Natural regulatory mechanisms 
which prevent occurrence of an autoimmune response in vivo, may be absent in our in 
vitro test systems. A more plausible explanation lies in the synthetic character of the 
peptides. A synthetic peptide does not use the normal route of processing and may end 
up as a new amino acid sequence in a HLA molecule of an APC. Responder T cells will 
recognize such a new epitope (‘neo-epitope’) in the context of self HLA class II, 
however this type of recognition is not necessarily related to indirect recognition of a 
naturally processed allopeptide. To our opinion, positive tests obtained with synthetic 















Figure 2: Proliferative response (in triplo) of healthy control PBMCs and UCB towards foreign synthetic peptides (HLA-
A1 and HLA-A2 respectively) and peptides corresponding to self (HLA-A2 and HLA-B7 respectively). Peptides were 
added in pools of 3 overlapping 30-mer peptides. Proliferation was measured at day 7. MRM: memory recall mix. 
Stimulation index=cpm of stimulated cells divided by cpm of unstimulated cells (medium control)  
 
 
Experimental set up 
Besides the antigenic stimulus, the responder cell population as well as the 
experimental setup of an in vitro assay is crucial. The optimal location to find recipient 
T cells with indirect allospecificity would be in or near the graft, since T cells migrate 
towards the graft after they have been triggered by recipient APCs presenting a donor 
derived peptide. In the graft they are supposed to exert their effector functions, which 
eventually may cause graft rejection. However, although the frequency of T cells with 
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indirect allospecificity during rejection may be 10-50 fold higher in the graft than in the 
periphery (54), for practical reasons most studies have been performed with PBMCs.  
In some studies donor antigens are added to PBMCs and the encounter of antigen, 
processing and presentation by autologous APCs will occur in the same environment 
as presentation to T cells. Only a few studies used a more sophisticated system, in 
which autologous APCs are purified by T cell depletion, incubation with antigen and 
finally added to responder T cells (42,47,49). To refine the antigen presenting cell 
population, we performed a costaining experiment of fragments of single antigens lines 
(SALs) and different cell populations (Figure 3). Only CD14+ cells (monocytes) showed 
costaining of PKH26 labeled SAL fragments and may be able to internalize the 
fragments, process them and finally present them in the context of HLA class II. This 
allows us to select the proper APC population and control the ratio between CD14+ 
APCs and T cells. In order to develop and validate a reliable in vitro system, 
standardization and quality controls within the different phases leading to indirect 
allorecognition are inevitable.  
As read out, most studies focus on the capacity of CD4+ cells to proliferate upon 
stimulation, but differ in other test characteristics. Proliferative capacity was measured 
upon coculture with synthetic peptides or cell fragments directly or after stimulation in 
limiting dilution assay (LDA). LDA quantifies the response by measuring the frequency 
of alloreactive cells, but involves prolonged in vitro culture systems, which may affect 
estimations of the true in vivo frequencies. More recently, the ELISPOT and flow 
cytometric approaches are used to estimate the number and phenotype of alloreactive T 
cells respectively. The ELISPOT is more sensitive than other techniques, such as MLC 
and ELISA, but represents a snapshot of the T cells response. Some of the cytokine-
producing cells may not proceed to proliferation or may undergo activation-induced 
cell death (68). The flow cytometric approach allows the individual characterization 
cells and the subsequent staining for cytokines refines the categorization of specific cell 
subsets, rather than just surface markers. Since a major feature of T cells with indirect 
allospecificity is their low frequency, a sensitive technique is required. In this respect, 
the phenotypic characterization of alloreactive T cells has an additional benefit above 
standard proliferation assays. 
When monitoring patients, it is essential to distinguish the response of naïve cells from 
that of primed donor reactive T cells. To develop an in vitro assay able to detect T cells 
with primed indirect allospecificity, one should focus on the detection of memory cells. 
Therefore, knowledge about the kinetics of a response is crucial. In our above described 
experiment using stained SAL fragments cocultured with stained PBMCs, it was 
possible to monitor the double positive stained cells at different time points (Figure 3). 
Within 24 hours after coculture, 25% of the CD14+ cells showed costaining of SAL 
fragments. This time span is in agreement with results of a recently performed study in 
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which a time period of 16-20 hours was found to be necessary for processing, 
intracellular routing and peptide presentation by APCs (34). Considering the use of 
primed responder cells and the uptake and processing of antigen within 1 day, one 
may question the need for a 7 day incubation period to detect memory cells as is used 
in most studies. Since cytokine secretion precedes proliferation upon stimulation, 
incubation of recipient PBMCs with donor antigens in ELISPOT was usually much 
shorter. Nevertheless, a study focusing on the kinetics of a memory is required to shed 











Figure 3: Costaining of SAL fragments on different cell populations. SAL fragments (stained with PKH26) were 
incubated for different hours with PBMCs (stained for different cell populations) (n=2). The percentage of double 





Various studies claim a relationship between the reactivity of T cells with indirect 
allospecificity and graft rejection. However, many different approaches are used and 
often essential controls are lacking. Hardly any study confirms the presence of indirect 
recognition using different approaches including the natural ligand. This is essential as 
all assays used so far have clearly disadvantages and pitfalls.  
The use of donor cells for fragmentation has our preference as antigen source for in 
vitro assays, since they contain the full HLA phenotype. However, no method to 
fragment cells has emerged as optimal, which is emphasized by the lack of consensus. 
Additionally, one should include control experiments when using fragmented cells to 
exclude recognition of alloantigens via the direct pathway. The exact knowledge of the 
alloantigen when using synthetic peptides is overshadowed by the ability to create neo-
epitopes. This turned out to be a big obstacle in defining specific response and requires 
at least the use of control peptides. Besides different antigenic sources, additional 
differences exist in test characteristics between studies in which most of them do not 
distinguish a naïve response from a memory response. In order to monitor the low 
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frequency of T cells with indirect allospecificity in vitro, it is essential to determine the 
kinetics and optimal conditions to detect a memory response.  
Detailed knowledge about the indirect allorecognition is required and it would be the 
right time to set up an international workshop to establish and validate a proper and 
robust assay to measure T cells with indirect allospecificity.  
 
MATERIALS AND METHODS 
 
Subjects and sample collection 
Peripheral blood mononuclear cells (PBMCs) from heparinized peripheral blood from 
healthy individuals or mononuclear cells from umbilical cord blood (UCB) were 
isolated by standard Ficoll density-gradient centrifugation. PBMCs were used 
immediately as responder cells in proliferation assays or were cryopreserved in RPMI 
1640 (Gibco, Paisley, United Kingdom) with 20% fetal calf serum (FCS, Gibco) and 10% 
dimethyl sulfoxid (DMSO, Fluka, Buchs, Switzerland). Cells were frozen at -70oC and 
stored in liquid nitrogen until further use.  
 
T cell clones 
The T cell line ThoU6 was obtained as described before (33). In brief, PBMC of 
individual Tho (DPB1*0301+, DRB1*0301-) were primed in the presence of a DR3 
peptide (aa 67-85: LLEQKRGRVDNYCRHNYGV) in RPMI 1640 supplemented with 
15% pooled human serum and gentamycin. After 7 days, the cultures were collected 
and restimulated with irradiated autologous feeder cells at a ratio of 10:1 and synthetic 
DR3 peptide. The line was cloned by limiting dilution in the presence of T cell growth 
factor (TCGF, Biotest, Germany) and irradiated autologous feeder cells. The CD4+ clone 
2014 was kept in culture by weekly stimulation with allogeneic PBMCs, rIL-2 in RPMI 
1640 complete medium with 10% pooled human serum.  
The CD4+ T cell clone 4.1 recognizes a HLA-A2 peptide (aa 101-122: 
CDVGSDWRFLRGYHQYAYDGKD) presented in HLA-DR1. The clone was 
maintained in culture by weekly stimulation with allogeneic PBMCs, allogeneic B cells, 
PHA, rIL-2 in Iscove’s MOD DMEM complete medium (Gibco) with 10% pooled 
human serum.  




Synthetic 20-mer overlapping peptides corresponding to residues 45-66 and 101-122 of 
1 and 2 domain from HLA-A2 alleles and synthetic 30-mer overlapping peptides 
representing the 1 and 2 domain of HLA-A1, -A2, -B7 and -B8 were synthesized by 
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solid-phase strategies on an automated multiple peptide synthesizer (SyroII, 
MultiSynTech, Witten, Germany). The purity of the peptides was determined by 
analytical reversed-phase HPLC. 
 
Cellular fragments 
Fresh or thawed PBMCs or SALs were used for fragment preparation. Fragmentation of 
PBMCs was performed using 4 different methods: 
 Method 1: PBMC were lysed by three cycles of freezing (liquid N2) and thawing 
(waterbath: 37oC) in RPMI 1640 complete medium at a concentration of 20x106 
cells/ml. The absence of whole intact cells was confirmed by microscopy (47,50).  
 Method 2: PBMC were lysed by three cycles of freezing (liquid N2) and thawing 
(waterbath: 37oC) in RPMI 1640 complete medium at a concentration of 20x106 
cells/ml, centrifugated at 16.000g for 20 minutes and the supernatant was collected.  
 Method 3: PBMC were lysed by three cycles of freezing (liquid N2) and thawing 
(waterbath: 37oC) in a Tris-EDTA-based buffer containing 1/5000 NP-40 (Fluka, 
74385), 0.1mM PMSF (Sigma P7626; Buchs, Switserland), 1/200 protease inhibitor 
mixture (Sigma, P8340) and 5 ng/ml soybean trypsin inhibitor (Sigma, T6522), 
centrifugated at 1000g for 2 minutes, and the supernatant was collected and further 
centrifugated at 14.000g for 45 minutes at 4oC (48,51).  
 Method 4: PBMC were lysed by three cycles of freezing (liquid N2) and thawing 
(waterbath: 37oC) in a Tris-EDTA-based buffer containing 1/8000 NP-40 (Fluka, 
74385), 0.1mM PMSF (Sigma, P7626), 1/800 protease inhibitor mixture (Sigma, 
8340) and 5 g/ml soybean trypsin inhibitor (Sigma, T6522), centrifugated at 2000g 
for 2 minutes (4oC), followed by a centrifugation step of the supernatant at 3000g 
for 2 minutes (4oC). Supernatant is harvested and further centrifugated at 100.000g 
for 60 minutes (4oC) in the buffer described above. The pellet is resuspended in 10-
20 l of solubilising solution: urea (Sigma, U0631), 2% CHAPS (Calbiochem, San 
Diego, USA) and protease inhibitor cocktail (Roche 1836153; Basel, Switserland). 
(personal communication)  
Fragmentation preparations are tested for protein concentrations using BCA protein 
assay kit (Pierce, Rockford, USA) and are stored at -70oC until further use.   
Fragmentation of SALs was similar to method 1, but one additional round of 
freeze/thawing was performed. Before use, the cell suspension was filtrated through a 
70- m cell strainer (Falcon; BD Bioscience, Bedford, MA, USA) to remove cell cloths.  
 
Proliferation assays: healthy control and UCB  
A total of 2x105 PBMCs of healthy individuals or mononuclear UCB cells were 
incubated with a pool of three synthetic HLA-derived peptides at a final concentration 
of 10 g/ml per peptide. As a positive control a memory recall mix (MRM) was used 
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containing tetanus toxoid (SVM, Bilthoven, The Netherlands), mycobacterium 
tuberculosis sonicate (Statens Serum Institute, Copenhagen, Denmark) and candida 
albicans (HAL Allergy, Haarlem, The Netherlands). The cells were plated out in U-
bottom 96-well plates (Costar, Cambridge, MA, USA) in a total volume of 200 l of 
RPMI 1640 complete medium supplemented with 5% autologous serum. After 6 days, 
wells were pulsed with 1 Ci of 3H-thymidine (Amersham International, Amersham, 
UK) and the cultures were harvested onto glass fiber filters 18 hours later. Proliferation 
was measured as 3H-thymidine incorporation by scintillation spectroscopy using a 
betaplate (Wallac, Turku, Finland).  
 
Proliferation assay: clone 4.1 
A total of 1x105 irradiated (30 Gy) A2-DR1+ PBMCs were prepulsed overnight with A2+ 
synthetic peptides at a final concentration of 10 g/ml per peptide or A2+/- cellular 
fragments at a final concentration of 1 g/well in Iscove’s MOD DMEM complete 
medium with 5% pooled human serum. Also, intact A2-DR1+, A2+DR1+ or A2-DR1- cells 
were kept overnight in Iscove´s medium. T cell clone 4.1, which was kept overnight at 
37oC in Iscove’s medium containing 100U/ml rIL-2, was then added at 5x103 cells per 
well. After 48 hours, wells were pulsed with 1 Ci of 3H-thymidine and proliferation 
was measured as described above.  
 
Enzyme linked immunospot (ELISPOT) assay: clone 2014 
A total of 1x105 irradiated (30 Gy) DR3-DP3+ PBMCs  were prepulsed overnight with 
DR3+ synthetic peptides at a final concentration of 10 g/ml per peptide or cellular 
fragments at a final concentration of 1 g/well Iscove’s MOD DMEM complete medium 
with 5% pooled human serum. T cell clone 2014, which was kept overnight at 37oC in 
Iscove’s medium containing 20U/ml rIL-2, was then added at 5x103 cells per well, 
centrifugated for a short time to concentrate the cells and stored for 2 hours at 37oC. 
Then, cells were harvested and transferred to an ELISPOT plate (MAHA S45 10, 
Millipore) precoated with a mouse antihuman IFN  monoclonal antibody (Mab 1-D1K; 
Mabtech, Nacka, Sweden) followed by blocking for 1 hour at 37oC with RPMI 1640 
containing 5% pooled human serum. Cells were incubated in the ELISPOT plate for 24 
hours at 4oC to allow spot formation. Plates were washed with PBS supplemented with 
Tween20 and the anti-IFN  detection antibody (Mab 7-B6-1-biotin; Mabtech, Nacka, 
Sweden) was added for 2 hours at room temperature (RT). The conjugate (extravidin 
alkalin phosphatase, Sigma E2636) was added for 1 hour at RT, followed by a washing 
step and addition of the substrate (BCIP-NBT tablet, Sigma B5655) for 5 minutes at RT. 
The reaction was stopped with tap water. The resulting spots were counted 
automatically using a Bioreader 3000 Pro (BioSys, Karben, Germany).   
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Pretransplant blood transfusions can improve graft function and survival after solid 
organ transplantation, but may also lead to activation of the immune response. The 
immunological mechanism leading to tolerance is not clear. We investigated the effect 
of a pretransplant leukocyte-containing blood transfusion on the phenotype and 
function of recipient lymphocyte subsets in individuals with previous exposure to HLA 
alloantigens by pregnancy and in individuals without previous HLA alloantigen 
exposure. In both patient groups, we detected an increase in the number of IFN  
producing T cells two weeks post-transfusion, reflecting activation of the recipient’s 
immune system. In patients with a prior exposure to HLA alloantigens, the increased 
frequency of IFN  producing cells was also found longer after transfusion, as well as 
after third party stimulation. Moreover, in the pre-sensitized recipients blood 
transfusion led to an increased number of natural killer (NK) cells. Microarray analysis 
confirmed activation of NK cell-related genes and other immune genes exclusively in 
this patient group. In conclusion, blood transfusion led to activation of the immune 
system in both patient groups, while the effect on NK cells only occurred in prior HLA 
exposed individuals. Markers that indicate a state of tolerance were not detected, 
leaving the mechanism of the immunomodulating effect of pretransplant blood 
transfusions as yet unsolved.  
 




Allogeneic blood transfusions expose a recipient to many soluble and cell-bound 
antigens. In particular, contaminant leukocytes are presumed to play an important role 
in interacting with the recipient’s immune system. Blood transfusions can induce 
humoral immunity as reflected by the formation of HLA alloantibodies or, as opposite 
effect, suppress the recipient’s cellular immune system (1). An example of clinical 
benefit of this transfusion-induced immunosuppression is the improved graft outcome 
in patients who received a pretransplant blood transfusion (2,3). However, the 
mechanisms leading to organ donor-specific hyporesponsiveness after blood 
transfusion are not understood. 
Because T cells play a central role in initiating an immune response towards the graft, it 
is possible that pretransplant blood transfusions may regulate these T cell responses 
ameliorating rejection and improve graft outcome. Several studies showed that 
allogeneic blood transfusion causes a shift in peripheral cytokine secretion by T helper 
(Th) cells from a Th1 phenotype towards that of a Th2 phenotype (1,4-6). Impairment of 
Th1 cytokine secretion may result in impairment of various functions of cellular 
immunity, including antigen processing, macrophage activation and cytotoxic T and 
natural killer (NK) cell functions. Storage of the blood product may contribute to 
immunoregulatory effects as well. It has been shown that soluble factors that arise in 
the blood product upon storage, like soluble HLA class I, class II and Fas ligand, can 
inhibit the mixed lymphocyte reaction (MLR) response and cytotoxic T lymphocyte 
(CTL) activity and induce apoptosis in Fas-expressing cells (7,8).  
In experimental animal models, regulatory T cells (Tregs) that actively suppress 
alloreactive T cells responses have been demonstrated (9-11). The dual effect of blood 
transfusion, i.e. antibody induction at one hand and transplantation tolerance at the 
other is hypothesized to depend on the degree of HLA-DR sharing between transfusion 
donor and recipient (12). Complete DR-mismatched transfusions induced more often 
HLA antibodies than transfusions that are shared for one HLA-DR antigen with the 
recipient, while the latter may induce Tregs mediating organ donor 
hyporesponsiveness (13,14). 
Our goal was to investigate the diverse effects of pretransplant blood transfusions on 
cellular immunity in two groups of recipients awaiting transplantation. We selected 
patients who received a pretransplant protocolled blood transfusion (PBT) before 
simultaneous pancreas-kidney transplantation and patients who received a donor-
specific transfusion (DST) before living-related kidney transplantation. Patients with a 
history of pregnancy or prior therapeutic transfusion were excluded from PBT from a 
donor selected by sharing one HLA-DR antigen. In contrast, DST recipients were 
selected because of previous pregnancies and received a transfusion from their 
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prospective kidney donor. This allows us to determine the impact of previous HLA 
exposure on the effect of a pretransplant blood transfusion.  
 
MATERIALS AND METHODS  
 
Recipients of a protocolled blood transfusion   
Between September 2004 and August 2007, patients on the waiting list for simultaneous 
pancreas-kidney transplantation (SPKT) received a protocolled blood transfusion (PBT) 
at our center (Leiden, the Netherlands) if they had no history of blood transfusions or 
pregnancy. Patients were transfused with one unit of one-HLA-DR matched, non-
leukocyte-depleted packed red blood cells, stored for less than 24 hours. The HLA 
phenotype of patients and donors was determined on a low resolution level by DNA-
based typing using PCR-SSP. The presence of anti-HLA antibodies in patient’s sera 
before and after transfusion was determined by complement-dependent cytotoxicity. 
Based on the HLA antibody specificities detected in current and historical patient sera 
and the prevalence of HLA antigens in the specific donor population, a virtual PRA 
(panel reactive antibody) was calculated. It reflects the chance that a cross-match with a 
potential donor will be positive.  
 
Table 1: Characteristics of PBT recipients. 
Sex Relation Mismatchesa        Virtual PRA (%) 
 P/BD  A/B/DR Pre 2 wk >10 wk 
PBT1 M/M unrelated 1/2/1 0 0 0 
PBT2 F/F unrelated 2/2/1 0 0 0 
PBT3 M/F unrelated 2/2/1 0 0 0 
PBT4 M/F unrelated 2/2/1 0 0 0 
PBT5 M/M unrelated 2/2/1 0 0 0 
PBT6 M/M unrelated 2/2/1 0 0 0 
PBT7 M/M unrelated 2/2/1 0 0 0 
PBT8 M/M unrelated 2/2/1 0 0 0 
PBT9 F/M unrelated 1/2/1 0 0 0 
PBT10 M/M unrelated 2/2/1 0 69 0 
P=patient, BD=blood donor. F=female, M=male. 
a HLA type: split level.
 
 
Patient blood samples were collected before and after PBT (2 weeks and >10 weeks), 
and from each donor a blood sample was derived from the blood product. The 
collection of material was approved by hospital ethical committee. Peripheral blood 
mononuclear cells (PBMCs) from patient and PBT donor were isolated from 
heparinized blood by density gradient centrifugation with Ficoll-Amidotrizoate 
(Pharmacy LUMC, Leiden, the Netherlands). Cells were washed twice with phosphate-
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buffered saline (PBS) and frozen in RPMI 1640 supplemented with L-glutamine 
(RPMI/glu, both from Gibco, Breda, the Netherlands), 20% fetal calf serum (FCS, 
Greiner, Alphen a/d Rijn, the Netherlands) and 20% dimethylsulfoxide (DMSO, Fluka, 
Buchs, Switserland). Cells were frozen at -70oC and stored in liquid nitrogen until use. 
Third-party cells, with a similar number of mismatches as those between recipient and 
blood donor, were obtained from healthy volunteers. For in vitro analyses, we selected 
PBMCs of all patients with transfusion-induced HLA alloantibodies (except for one 
PBT recipient, due to lack of material). A random selection was made of the patients 
without HLA alloantibodies. Ten PBT recipients were selected for in vitro analyses. 
Their characteristics are shown in Table 1.  
 
Recipients of a donor-specific transfusion 
A donor-specific blood transfusion (DST) was given before living-related kidney 
transplantation in order to detect or boost historical sensitization. The selection of DSTs 
was independent of HLA phenotype, but equals the prospective kidney donor. Women 
with previous pregnancies were transfused with one unit of non-leukocyte-depleted, 
less than 24 hours stored packed red blood cells. Patient and donor PBMCs were 
collected and processed as described above. Fourteen DST recipients were selected for 
in vitro analyses, of whom half developed anti-HLA antibodies upon transfusion. Their 
characteristics are shown in Table 2.  
 
Table 2: Characteristics of DST recipients. 
Sex Relation Mismatchesa             Virtual PRA (%) 
 P/BD  A/B/DR Pre 2 wk >10 wk 
DST1 F/M partner 2/2/1 0 0 0 
DST2 F/M partner 2/1/1 0 0 0 
DST3 F/F daughter 1/1/0 0 0 0 
DST4 F/M son 1/1/1 0 0 0 
DST5 F/M partner 2/2/1 0 0 0 
DST6 F/F sister 0/2/2 0 0 0 
DST7 F/M partner 1/1/1 0 0 0 
DST8 F/F daughter 1/1/1 0 29 78 
DST9 F/M unrelated 2/2/2 71 80 93 
DST10 F/M partner 1/2/2 0 70 39 
DST11 F/F daughter 1/1/1 0 77 78 
DST12 F/M son 0/1/0 0 46 45 
DST13 F/M unrelated 2/1/1 0 37 37 
DST14 F/M partner 0/1/2 0 10b 0 
P=patient, BD=blood donor. F=female, M=male. 
a HLA type: split level 





Flow cytometry  
For cell surface staining of lymphocyte subsets, activation markers, memory cell 
subsets and regulatory T cells (Tregs), thawed patient PBMCs were stained for 30 min 
at 4oC with fluorchrome-conjugated anti-human monoclonal antibodies (mAbs). 
General panel: anti-CD45 APC, anti-CD3 APC-Cy7, anti-CD4 PacB, anti-CD8 Amcyan, 
anti-CD14 PE-Cy7, anti-CD19 PE-Cy7, anti-CD56 AF700 and anti- TCR PE from BD 
Biosciences Pharmingen (San Diego, CA, USA). Activation panel: anti-CD3 PacB, anti-
CD4 AF700, anti-CD8 FITC, anti-CD25 APC-Cy7, anti-CD28 APC, anti-CD14 PE-Cy7, 
anti-CD19 PE-Cy7 and anti-CTLA-4 PE-Cy5 (BD Biosciences Pharmingen), anti-HLA-
DR PE-TxRed (Invitrogen, Eugene, OR, USA) and anti-CD127 PE (Beckman Coulter, 
Fullerton, CA, USA). Memory panel: anti-CD3 PacB, anti-CD4 APC-Cy7, anti-CD8 PE, 
anti-CD28 APC, anti-CD14 PE-Cy7 and anti-CD19 PE-Cy7 (BD Biosciences 
Pharmingen), anti-CD27 AF700 (eBioscience, San Diego, CA, USA), anti-CCR7 FITC 
(R&D systems, Minneapolis, MN, USA) and anti-CD45RA PE-TxRed (Invitrogen). Treg 
panel: anti-CD3 PacB, anti-CD4 AF700, anti-CD8 Amcyan, anti-CD25 APC-Cy7, anti-
CD14 PE-Cy7 and anti-CD19 PE-Cy7 (BD Biosciences Pharmingen), anti-CD127 PE 
(Beckman Coulter), anti-CCR7 FITC (R&D systems) and anti-CD45RA PE-TxRed 
(Invitrogen) and anti-Foxp3 APC (eBioscience). mAbs were used in optimal titrated 
concentrations. Phenotypic characterization of CTLA-4 and Foxp3 required subsequent 
intracellular staining. To permeabilize cells for CTLA-4 staining, PBMC were incubated 
for 15 min with Intrastain fixative A (Glostrup, Denmark), washed, followed by 15 min 
incubation with fixative B and anti-CTLA-4 PE-Cy5. Intracellular staining for Foxp3 
was performed using the APC-conjugated anti-Foxp3 Staining Set. A rat IgG2a isotype 
control (eBioscience) served as a negative control. To ensure correct measurement 
settings, compensation beads (uncoated and coated with anti-mouse Ig ) stained with 
mAbs conjugated with each of the fluorchromes were used. Data were acquired using 
the BD LSR II flow cytometer (BD Biosciences) equipped with a 488nm laser, a 405nm 
laser, a 633nm laser and a 325nm to detect all the fluorescence parameters plus two 
scatter parameters. Data were analyzed using FACSDiva software (BD Biosciences).  
 
Elispot assay 
Reactivity of patient cells towards cells of the specific blood donor or third party was 
measured in the IFN  enzyme-linked immunosorbent spot (Elispot) assay. First, 96-
well Elispot plates (Millipore, Eschborn, Germany) were coated with a mouse anti-
human IFN  monoclonal antibody (Mab 1-D1K; Mabtech, Nacka Strand, Sweden) and 
left at 4oC overnight. Plates were blocked for 1 hour at 37oC with RPMI/glu containing 
5% pooled human serum (HS). Responder PBMCs at a concentration of 1x105 (in 100 μl) 
were stimulated with 2x105 irradiated (4500 Rad) stimulator PBMC (in 50 μl) in 
triplicate wells in RPMI/glu containing 10% HS. Incubation was for 24h on an Elispot 
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plate (short assay) or for 4d in a 96-well round bottom plate (Costar , Cambridge, MA, 
USA) followed by 24h on an Elispot plate (long assay). Medium and third-party donor 
cells (with a similar number of mismatches with the patient as the blood donor) were 
negative controls, whereas phytohemagglutinin (PHA, Remel Inc., Lenexa, KS, USA) 
served as a positive control. 48h and 4d after stimulation supernatant was collected for 
cytokine analysis.  
After incubation (37oC, 5% CO2) plates were washed with PBS supplemented with 
Tween20 and the anti-IFN  detection antibody (Mab 7-B6-1-biotin; Mabtech, Nacka 
Strand, Sweden) was added for 2 hours at room temperature (RT). The conjugate 
(extravidin alkalin phosphatase, Sigma, St. Louis, MO, USA) was added for 1 hour at 
RT, followed by a washing step and addition of the BCIP/NBT substrate (Mabtech, 
Nacka Strand, Sweden) for 5 minutes at RT. The reaction was stopped with tap water. 
The resulting spots were counted automatically using the AID Elispot Reader System 
version 4.0 (AID, Strassberg, Germany). 
 
Microarray analysis   
Pre-transfusion and 2wk post-transfusion cryopreserved cells were thawed, washed 
twice in PBS and preserved in RNAlater solution (Qiagen, Chatsworth, CA, USA). Total 
RNA was isolated from the samples using the RNeasy® mini Kit (Qiagen) following the 
manufacturer’s instructions and treated with DNase (Qiagen) on the spin columns. 
RNA quantity was assessed with a spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) that determined the optical density (OD) at 260 nm. RNA 
quality was assessed using the Agilent RNA 6000 Nano LabChip® Kit with the Agilent 
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Integrity of RNA was 
visualized by the 28S:18S ratio and the RNA integrity number (RIN). In our samples, 
the 28S:18S ratio, which ideally approaches 2, has a mean value of 1.9. A high RIN 
(scale from 0 to 10) is associated with less degradation and had a mean value of 7.9 in 
our samples. We used the Illumina® TotalPrep RNA Amplification Kit (Ambion, 
Austin, TX, USA) to amplify RNA for hybridization on Illumina BeadChips. To 
synthesize first strand cDNA by reverse transcription, we used 300-500 ng of total RNA 
from each sample. Following second strand cDNA synthesis and cDNA purification 
steps, the in vitro transcription for synthesis of cRNA was prepared overnight for 8h. 
The cRNA (1100 ng) of pre- and post-transfusion PBMCs was hybridized to Illumina 
HumanRef-8 v3.0 BeadChips (Illumina, San Diego, CA, USA), which contains over 
24,000 genes. Gene expression profiles in pre- and post-transfusion samples were 
analyzed pair wise using the Illumina BeadStudio software. Only significantly 









































































The Wilcoxon signed rank test for matched pairs was performed to determine 
differences between pre- and post-transfusion cellular responses in Elispot and 




Phenotypic changes after transfusion  
To determine whether pretransplant blood transfusions had caused a shift in different 
cell populations, pre- and post-transfusion (2wk and >10wk) recipient PBMCs were 
stained for cell surface and intracellular markers.  
With regard to the activation or memory status of the cells, no significant changes were 
observed after a PBT or DST. Tregs, defined as CD4+CD25+Foxp3+CD127low cells, 
accounting for about 4% of the total CD3+ T cell population, were not affected by a 
pretransplant blood transfusion. However, the proportion of NK cells (CD3-CD56+) 
within the CD45+ cell population was altered after pretransplant blood transfusions, 
albeit in different directions dependent on whether the recipient was prior exposed to 
foreign HLA antigens or not (Figure 1). In PBT recipients the proportion of NK cells 
rather decreased, in particular after a longer interval (p=0.08), whereas in DST 
















Figure 1: Change in proportion of NK cells (CD3-CD56+) after PBT (A) or DST (B). Recipient pre-transfusion or post-
transfusion (2wk or >10wk) PBMCs were thawed and labeled with anti-CD45, anti-CD3 and anti-CD56 monoclonal 
antibodies. Statistics: Wilcoxon matched pairs test. * P-value<0.05. PBMCs of 3 PBT recipients (PBT1, 2, 3) and 3 
DST recipients (DST1, 5, 8) (black lines) were selected for microarray analysis.  
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IFN  production by recipient cells 
The effect of pretransplant blood transfusion on the functionality of recipient 
lymphocytes was measured by means of an IFN  Elispot assay. To be able to measure 
the number of IFN  producing cells, pre- and post-transfusion (2wk and >10wk) 
PBMCs of PBT and DST recipients were stimulated for 24h with blood donor (BD) 
PBMCs or third party (3P) PBMCs. As shown in Figure 2A, an increased number of 
IFN  producing cells was found in PBT recipients after stimulation with the specific BD 
(p=0.02), but not after 3P stimulation (p=0.91). The increase in IFN  producing cells had 
disappeared after a time-period longer than 10 weeks after PBT. As shown in Figure 2B, 
a similar reactivity of 2wk post-transfusion PBMCs of DST recipients was found 
(p=0.003). The IFN  producing cells persisted more than ten weeks after DST (p=0.004). 
However, besides the increased number of IFN  producing cells after specific 
stimulation, an increase was detected after third party stimulation (p=0.005 and p=0.004 
for 2wk and >10wk respectively). We checked whether the NK cells were responsible 
for IFN  production in the Elispot assay by performing a CD56+ depletion assay, but 
this was not the case (data not shown). The production of IFN  was attributed to 
recipient T cells. 
Naive T cell responses towards the specific blood donor, as determined in 5d Elispot, 


















































































Figure 2: IFN  Elispot of PBT recipients (A) and DST recipients (B). Recipient pre-transfusion or post-transfusion (2wk 
or >10wk) PBMCs were stimulated for 24h with irradiated blood donor PBMCs (BD) or third party PBMCs (3P) at a 


















Figure 3: Overview of fold change of all genes after PBT (n=3; y-axis) or DST (n=3; x-axis). Microarray analysis of a 
total of 9606 genes resulted in higher number of genes that were up-regulated or down-regulated after DST (472 and 
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To detect the influence of pretransplant blood transfusions on gene expression profiles, 
RNA of pre-transfusion and 2wk post-transfusion samples was analyzed using 
microarray analysis. RNA samples of PBT recipients 1, 2, 3 and DST recipients 1, 5, 8 
showed good RNA quality and were selected for hybridization. A striking difference in 
fold change of genes after DST or PBT was observed. Figure 3 shows the difference in 
gene expression between pre-transfusion and 2wk post-transfusion samples analyzing 
9606 genes. Many genes have been up- or down-regulated after DST, while gene 
expression is less affected in PBT recipients. A mean fold change in gene expression of 
2-fold or more after DST resulted in 472 genes that were up-regulated and 206 genes 
that were down-regulated. In contrast, respectively 27 and 0 genes were at least 2-fold 
increased or decreased after PBT.  
 
As the number of NK cells was increased in the DST group only, we specifically 
analyzed NK cell-related genes and identified 7 genes with a mean increase of at least 
2-fold after DST. Expression of these genes remained unaltered, or even decreased in 
PBT recipients (Figure 4). The first three genes encode for the lytic proteins granzyme 
A/K and perforin, which are involved in the effector function of cytotoxic T cells and 
NK cells. The other genes (KLRF1, KIR2DL3, CD94 and CD160) encode for proteins 
expressed on NK cells only.  
 
 
Figure 4: Expression of NK cell-related genes in PBT (n=3) and DST recipients (n=3). Values are shown as mean ± 
sd. The dotted line represents the level of no change after transfusion (post/pre trf=1). KLRF1=killer cell lectin-like 





The goal of this study was to gain more insight into the effect of pretransplant blood 
transfusions on the recipient’s cellular immune system. Pretransplant blood 
transfusions can cause immune activation as well as immune suppression, but the exact 
immunological mechanisms of these effects are still unsolved. The present study shows 
that both a PBT and DST activate the recipient’s immune system as reflected by an 
increased number of IFN  producing cells 2 weeks post-transfusion. This is in 
agreement with previous studies that observed an increased frequency of helper and 
cytotoxic T cells (HTLp and CTLp respectively) (15,16), irrespective of the degree of 
HLA matching between recipient and blood donor (17,18). However, contradictory 
results are also reported, such as a decrease in CTLs after a HLA-shared blood 
transfusion (19,20) or no change at all (21). The question why T cell activation after a 
first stimulus by blood transfusions would lead to hyporesponsiveness towards a 
subsequent organ donor has been addressed before. Terasaki (22) hypothesized that the 
graft acts as a second stimulus and concurrent immunosuppressive drug treatment 
particularly deletes these reactivated T cells. This could indeed explain why increased 
HLTp and CTLp frequencies are associated with better graft survival. However, this 
cannot explain the difference on graft survival between HLA-DR shared and non-
shared transfusions.  
We investigated whether Tregs are activated after a pretransplant blood transfusion. It 
has been hypothesized that especially after HLA-DR shared blood transfusion Tregs 
may play an important role (13). This was supported by experimental animal models, 
in which Tregs were generated after DST, able to transfer tolerance to naïve mice 
(10,23). Tregs (CD4+CD25+Foxp3+CD127low) in our patient population, accounted for 
about 4% of CD3+ cells, but their proportion was not changed shortly or long after PBT 
or DST. Moreover, when we analyzed intracellular and cell surface activation markers, 
there was no change in the number of activated cells, whereas a higher activity of blood 
donor-specific recipient T cells was found 2 weeks post-transfusion by Elispot analysis. 
This suggests that while the percentage of activated cells remains the same, their 
effector function may be increased. The contribution of Tregs may be missed during in 
vitro investigation of peripheral blood cells. Encounter of alloantigens and initiation of 
the immune response occurs in lymphoid organs, which is the presumed site for 
immune regulatory mechanisms to take place. Increased numbers of Tregs were found 
in lymph nodes as well as in the graft upon transplantation (11). Moreover, a second 
boost by the graft may be necessary for sufficient Treg numbers to develop (24). Our 
phenotypic analyses of recipient PBMCs do not give any indication on the role of Tregs 
to explain a beneficial blood transfusion effect, but rather suggest activation of T helper 
1 cells.   
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The investigation of PBT recipients as well as DST recipients provides information 
about the effect of former HLA alloantigen exposure on blood transfusion outcome. 
HLA antibody formation occurred more frequently after DST than after PBT. 
Additionally, after DST recipient T cells were affected in a broader way. In contrast to 
PBT recipients, DST recipients not only showed an increased number of IFN  
producing T cells for a longer interval after transfusion, but also against a third party 
estimated in the Elispot assay. This profound T cell activation may account for the 
increased number of NK cells (CD3-CD56+) that we observed after DST in phenotypic 
analysis. CD4+ T cells can stimulate NK cells via cytokines, such as IFN , encouraging 
the NK cells to obtain effector functions. NK cells are cells of the innate immune system 
that can kill target cells through the release of lytic proteins, such as perforin and 
granzymes. They express activating and inhibitory surface molecules that interact with 
specific HLA class I molecules on the target cells. (25). Microarray analysis showed 
that, indeed, there was an increased expression in DST recipients of genes that encode 
for proteins involved in the cytolytic process by NK cells, such as perforin, granzyme A 
and K. There was also an increased expression of the receptors KLRF1, or NKp80 (an 
activating receptor) and KIR2DL3, an inhibitory receptor. Genes encoding for CD94 
and CD160, predominantly expressed on NK cells, were increased as well. The effect on 
NK cells may be the result of missing self antigens on the blood donor leukocytes (26), 
as each blood donor expresses an HLA class I ligand (HLA-C or Bw4) for the receptors 
on recipient NK cells. However, PBT donors also express missing self antigens, 
showing that this hypothesis cannot account for the difference in NK cell activation 
between PBT and DST recipients. Previous studies that investigated the effect of blood 
transfusions on NK cells, reported an impaired NK cell reactivity (27,28), similar as we 
observed after PBT.  
Not only NK cell-related genes were up- and down-regulated after DST, but many 
other genes, a phenomenon not observed after PBT. It is likely that these differences 
between PBT and DST recipients in gene expression profiles reflect the primary and 
memory immune responses respectively. As all DST recipients were primed for HLA 
alloantigens by pregnancy, T cells of DST recipients may respond in an accelerated and 
heightened manner towards alloantigens as compared to PBT recipients. Other factors 
that may influence the difference between PBT and DST recipients are the underlying 
disease and HLA compatibility between recipient and blood donor. All PBT recipients 
had developed end-stage renal disease caused by type I diabetes mellitus, which was 
not the case in DST recipients. It is not likely that differences in HLA compatibility are 
of notice. Patients who received a DST matched for one HLA-DR antigen (n=8), thus 
comparable with PBT recipients, showed similar findings in Elispot and phenotypic 
analysis compared with the whole group (n=14). In microarray, all 3 PBT and DST 
recipients were matched for 1 HLA-DR antigen with the blood donor. 
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In conclusion, PBTs as well as DSTs activated the recipient’s T cell compartment, 
whereas DSTs also activated NK cells. While clinical transplantation outcome is 
improved in patients who received a PBT (29), we were not able to detect a parameter 
for transplantation tolerance in these patients.  
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Microchimerism is the presence of a small percentage of allogeneic hematopoietic cells 
in an individual that can exist following blood transfusion, transplantation and 
pregnancy. It is associated with immunological tolerance and may be involved in the 
beneficial transplant outcome after pretransplant blood transfusions. Our goal was to 
determine the level of microchimerism in patients who received a leukocyte-containing 
pretransplant blood transfusion, while evaluating the conventional nested PCR 
technique for microchimerism detection. In one patient, donor-derived cells were 
detected two weeks post-transfusion. In the other ones, donor cells were absent or 
results were difficult to interpret due to technical limitations of the nested PCR 
technique. Therefore, we proposed a novel technique that combines flow cytometry-
based cell sorting and confirmation of donor origin by subsequent quantitative PCR 
analysis. First analyses suggest that this approach is a robust and reliable approach for 
the detection of microchimerism. Once this assay is validated, it is possible to establish 
the occurrence of microchimerism after pretransplant blood transfusions and determine 
its role in transplantation tolerance.  
 




Hematopoietic chimerism can be defined as the coexistence of hematopoietic lineage 
derived cells with a distinct genetic background in an individual. It may be detected 
following cell transfer during pregnancy in the mother and in the fetus, but also after 
blood transfusion, stem cell transplantation, and solid organ transplantation. The 
existence of 1-100% donor cells in the recipient is called macrochimerism. In contrast, 
microchimerism refers to the state in which the percentage of circulating donor cells is 
low (<1%) (1). Whereas complete or macrochimerism is the purpose of hematopoietic 
stem cell transplantation, microchimerism is often found after solid organ 
transplantation through migration of passenger hematopoietic cells of donor origin 
from the graft into the peripheral circulation and tissues of the recipient. Many reports 
exist on microchimerism after transplantation of liver (2), kidney (3-5), heart (6) and 
lungs (7,8), even up to 30 years after the original transplantation. After blood 
transfusion, donor cells in the recipient’s peripheral blood are rapidly cleared within 5-
7 days (9,10), although in case the recipient and blood donor share an HLA haplotype 
donor cell-derived DNA can be detected for several weeks (11). In 
immunocompromised patients due to trauma injury, long-term (  2 years) donor 
microchimerism has been found, even after transfusion of leukocyte-reduced blood 
products (12).  
Detection of peripheral blood microchimerism may help to understand the 
immunological effects that occur after pregnancy, blood transfusion and 
transplantation. Fetal cell microchimerism is associated with maternal autoimmune 
diseases, but, in contrast, it may favor the maternal health post-partum (13). Initially, 
microchimerism was detected in patients who showed excellent graft function and 
required minimal immunosuppressive therapy (14). Although it is often questioned 
whether microchimerism is the cause or consequence of long-term allograft survival 
(15), several observational studies report now on a causal role of circulating donor cells 
in the induction of tolerance (16-18). Especially, microchimerism early after 
transplantation (< 2 months) correlated with a low incidence of acute allograft rejection 
(19). However, it is not clear whether microchimerism indicates a tolerant state that 
allows reduction of immunosuppressive treatment in the individual patient.   
For obvious reasons it is postulated that in order to obtain microchimerism, donor-
reactive T cells in the recipient must be eliminated or suppressed. Elimination can 
occur when donor and recipient antigen-presenting cells (APCs) coexist in large 
quantities (macrochimerism), thereby deleting T cells with high affinity for donor or 
recipient APCs in the thymus (20). Such conditions exist after hematopoietic stem cell 
transplantation and require strong immunosuppressive conditioning of the recipient, 
associated with impaired immunocompetence. Experimental models focused on less 
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toxic approaches by blocking co-stimulatory signals with monoclonal antibodies 
(mAbs), impairing the ability of T cells to respond to alloantigens (20). Anti-CD154 
antibodies that target the CD40-CD40L co-stimulatory pathway in combination with 
exposure to donor hematopoietic stem cells, derived from bone marrow or blood, 
resulted in allogeneic chimerism and tolerance (21,22). In this process, induction of 
CD4+ regulatory T cells may be responsible for the maintenance of tolerance (23).  
Microchimerism may be one of the mechanisms accounting for the beneficial effect of 
pretransplant blood transfusions on transplant outcome (24). However, a study in mice 
demonstrated that donor-recipient microchimerism, obtained by a pretransplant donor-
specific transfusion under the cover of a depleting anti-CD4 antibody, is not required in 
itself for tolerance induction (25).  
Opposite to tolerance induction, in several studies microchimerism was identified as a 
risk factor for allograft rejection (26-28). It is conceivable that the nature of donor-
derived cells may underlie this phenomenon, while contradictory results may also be 
explained by different detection techniques and a difference in control time points 
studied (29). Initially, the presence of the sex-determining region-y gene (SRY) was 
used as a marker of microchimerism to detect male cells in female recipients (2). 
Quantitative polymerase chain reaction (PCR) of the SRY gene is a reproducible and 
sensitive technique (29), but is restricted to sex-mismatched combinations only. The 
human leukocyte antigens (HLA) are a broader applicable target for microchimerism 
detection, as they are highly polymorphic (30) and thus frequently mismatched 
between two individuals. Classical and quantitative (real-time) PCR techniques for 
detection of HLA alleles are frequently used and suitable for detection of 
macrochimerism and microchimerism (29). The sensitivity of these conventional PCR 
techniques can be increased by the introduction of a preliminary PCR that first 
amplifies the generic HLA class I (31) or class II locus (32), followed by a second-round 
PCR with sequence-specific primers (nested PCR), although this may lead to false 
positive reactions.  
In this chapter, we describe and discuss three topics: 1) the detection of 
microchimerism in patients who received a pretransplant leukocyte-containing blood 
transfusion, 2) the use of the nested PCR technique and 3) the development of a new 
technique that combines flow cytometry-based cell sorting and real-time PCR.  
 
MATERIALS AND METHODS 
 
Patients and blood samples 
Seven patients were selected for microchimeric analyses after blood transfusion. While 
on the waiting list for simultaneous pancreas-kidney transplantation (SPKT), they 
received a protocolled blood transfusion (PBT) in case they did not have a history of 
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pregnancy or therapeutic blood transfusions. Blood donors were selected on basis of 
having one HLA-DR match with the patient and a negative red cell and leukocyte cross 
match. One unit of fresh, <24 hours stored, non-irradiated, plasma-reduced whole 
blood was administered. Patient blood samples were collected before and after PBT (2 
weeks and >10 weeks) and from each donor a blood sample was derived from the 
blood product. The collection of material was approved by ethical committees of the 
Leiden University Medical Center (Leiden, the Netherlands). Peripheral blood 
mononuclear cells (PBMCs) from patients and blood donors were isolated from 
heparinized blood by density gradient centrifugation with Ficoll-Amidotrizoate 
(Pharmacy LUMC, Leiden, the Netherlands). The cells were washed twice with 
phosphate-buffered saline (PBS) and frozen in RPMI 1640 supplemented with L-
glutamine (RPMI/glu, both from Gibco, Breda, the Netherlands), 20% fetal calf serum 
(FCS, Greiner, Alphen a/d Rijn, the Netherlands) and 20% dimethylsulfoxide (DMSO, 
Fluka, Buchs, Switserland). The cells were frozen at -70oC and stored in liquid nitrogen 
until use.  
 
DNA isolation 
DNA was prepared, after thawing of cryopreserved mononuclear cells, by a salting out 
method (33), precipitated with ethanol, and resuspended in TE buffer (manufactured in 
our lab). All samples were typed for HLA class I and HLA class II using the polymerase 
chain reaction with sequence-specific oligonucleotide probes (PCR-SSO technique). 
Table 1 shows the HLA type and sex of the patients and donors.  
 
Nested polymerase chain reaction (nested PCR) 
A nested PCR, consisting of two successive rounds of PCR, was performed for the 
detection of HLA class I microchimerism. First-round PCR (generic amplification) was 
carried out in a mixture containing dH2O, Tris-EDTA based buffer (10x MG buffer; 
manufactured in our lab), 0.2 mM of each dNTP, 0.1 U/ l taq polymerase and 0.5 
pmol/ l of the forward (5’) and reverse (3’) HLA locus-specific primers (HLA-A and 
HLA-B). If feasible, PCR reactions were carried out in a volume of 50 l containing 0.5 
g of DNA. PCR amplification was done in a MJ Dyad discipline PCR machine (Bio-
Rad, Hercules, CA, USA). After an initial denaturation step of 3min at 95oC, 32 cycles 
were performed: 95oC for 60s, 65oC for 60s, 72oC for 3min, and time extension at 72oC 
for 10min.  
The amplification product was diluted 1:100 in H2O and 5 l of the diluted product was 
used as input in a second round of amplification with forward and reverse sequence-
specific primers for the HLA molecules of the blood donor. The reaction mixture 
contained dH2O, 10x MG buffer, loading buffer (10x LB; manufactured in our lab), 0.2 
mM of each dNTP, and 0.1 U/ l taq polymerase and 1.6 pmol/ l of each primer. The 
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PCR program was as follows: denaturation for 2min at 94oC, 10 cycles: 94oC for 10s, 
65oC for 60s, 20 cycles: 94oC for 10s, 61oC for 50s, 72oC for 30s and time extension at 72oC 
for 3min.  
PCR products were subsequently analyzed by agarose gel electrophoresis. PBMCs of 
one patient were further characterized by sequence analysis. The PCR product formed 
by the specific A11.2 primer combination in the second (nested) PCR was sequenced by 
the 3130 XL sequencer (Applied Biosystems, Foster City, CA, USA) and analyzed with 
SBT Engine software.  
 
Flow cytometry-based cell sorting  
Cell mixtures of 10% (1:10, donor:patient) and 0.1% (1:1000) were prepared from pre-
transfusion PBMCs of patient 7 and donor PBMCs to mimic microchimeric situations. 
To prevent non-specific binding of monoclonal antibodies (mAbs) to Fc receptors, 
thawed patient and donor PBMCs were blocked with a non-specific and non-
biotinylated antibody (FcR blocking Reagent, Miltenyi Biotec, Bergisch Gladbach, 
Germany). Then, cell mixtures were stained for 30min at 4oC with an anti-HLA-B51/B35 
biotin-labeled antibody (HDG8D9; manufactured in our lab), Alexa 647-conjugated 
streptavidin (Invitrogen, Eugene, OR, USA), anti-CD45 FITC and anti-CD14-PE from 
BD Biosciences Pharmingen (San Diego, CA, USA). The 10% mix was used to define the 
gating strategy for CD45+CD14-HLA-B35+ donor lymphocytes and CD45+CD14-HLA-
B35- patient lymphocytes, whereas the 0.1% mix (1:1000) was prepared for sorting these 
cell subsets. Cell staining and sorting occurred with the BD FACSAriaTM cell sorter (BD 
Biosciences, San Jose, CA, USA), equipped with a 576/26 nm filter for PE-labeled cells, a 
530/30 nm filter for FITC-labeled cells and a 660/20 nm filter for Alexa 647-labeled cells. 
The sorted cell fractions, obtained using the yield sort settings, were used in 
subsequent quantitative real-time PCR analysis.  
 
Real-time PCR  
DNA was isolated as described before from the sorted cell fractions, the original 0.1% 
chimeric cell suspension and PBMCs of patient 7 and the blood donor. Amplification 
was carried out in a mixture containing 5 l DNA-cellysate, dH2O, SYBR Green mix 
(Bio-Rad, Hercules, CA, USA) and 4 pmol/ l HLA-A1/A11 or 0.4 pmol/ l HLA-DR7 
forward and reverse primers using a real-time PCR machine (MyiQ, Bio-Rad). Primers 
for the human hematopoietic cell kinase (HCK) gene were used for normalization of 
the variable content of human DNA (internal standard) in each sample (34). The PCR 
program was as follows: denaturation for 5min at 94oC, 10 cycles: 94oC for 15s, 65oC for 
45s, 30 cycles: 94oC for 15s, 61oC for 45s, 72oC for 30s, followed by 95oC for 60s, 55oC for 
60s and 80 steps of 0.5oC/step increase of temperature from 55oC to 95oC to create the 
melt curve. For each reaction, the PCR cycle number that generated the first 
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fluorescence signal above a threshold (the threshold cycle, Ct) was calculated with Bio-
Rad iQ5 software. The delta Ct ( Ct) was calculated as follows: Ct obtained with 





The characteristics of patients and blood donors are shown in Table 1. The selection of 
blood donors was based on one HLA-DR match with the recipient, as shown in bold, 
and a mismatch for the other HLA-DR allele as well as the HLA-A and HLA-B alleles.  
 
Table 1: Patient and donor characteristics. 
 HLA type patienta HLA type blood donora Sex 
 HLA-A HLA-B HLA-DR HLA-A HLA-B HLA-DR Patient Donor 
P1 2, 24 7, 44 1, 4 1, 3 13, 62 4, 7 F F 
P2 2, 3 58, 55 4, 13 1, 24 49, 51 4, 11 M M 
P3 1, 3 7, 8 4, 17 1, 26 38, 41 13, 17 M M 
P4 2, 30 18, 60 13, 17 11, 28 14, 35 13, 14 M M 
P5 2, 11 8, 27 4, 17 1, 3 18, 57 13, 17 M F 
P6 2 7, 60 4, 17 1, 33 8, 44 1, 17 M M 
P7 2 7, 62 4, 17 1, 11 35, 60 4, 7 M F 
a HLA type: split level. M: male; F: female.  
 
 
Microchimerism after blood transfusion 
Amplification of post-transfusion DNA of patient 7 showed positive bands on agarose 
gel when donor-specific primers were used. In the other 6 patients, we found no 
positive bands. Results of the nested PCR of P7 and one other patient (P5) are shown in 
Figure 1A and 1B respectively. For each HLA class I allele, two different combinations 
of forward and reverse primers were compared (Figure 1D).  
In the left part of Figure 1A a clear dilution is shown in lane 1 to 7 of positive DNA (see 
Figure 1C for order) for each HLA-A specific primer. However, primer combination 
A1.1 depicted the negative control DNA as a positive sample, which makes 
interpretation of the results obtained with this primer combination difficult. Chimeric 
donor cells were detected, in duplicate, in the 2 wk post-transfusion samples, while 
absent in the pre-transfusion test samples when the HLA-A1.2, -A11.1 and -A11.2 
primer combinations were used. No cross reactive response of these primers was 
observed with HLA alleles corresponding to the patient (data not shown). The positive 
bands are of similar intensity as the positive DNA control in lane 5, which means that 












1:20000). Sequence analysis of the 2 wk post-transfusion PCR product acquired by 
using primer combination A11.2, confirmed donor origin.  
The HLA-B35 specific primers failed, while neither positive DNA nor chimeric cells 
after transfusion could be detected. When using the HLA-B60 primers, false-positive 
reactions (prior to transfusion and positive water controls) were found. Thus, chimeric 
cells after blood transfusion were detected in P7 with the primers specific for the HLA-
A alleles, but could not be confirmed with the HLA-B specific primers. More than 10 
weeks after transfusion, chimeric cells had disappeared below detection level as none 


























































Standard dilution Test samples 
1 1:1 10 pre-transfusion 
2 1:100 11 pre-transfusion 
3 1:1000 12 H2O 
4 1:10000 13 2 wk post-transfusion 
5 1:20000 14 2 wk post-transfusion 
6 1:100000 15 H2O 
7 1:1000000 16 >10 wk post-transfusion 
8 negative 17 >10 wk post-transfusion 














 Primers 5’ 3’ 
 HLA-A gaaac(gc)gcctctg(tc)ggggagaagcaa tctggtcctgagggagagga 
 HLA-B gaggagcgaggggaccgca ataggtcg(cg)cggggatgg(gc) 
P5 A1.1 cgacgccgcgagccagaa caggtatctgcggagcccg 
 A1.2 ttcctccgcgggtaccgg gctctctgctgctccgccg 
 A3.1 acggaatgtgaaggccca cactccacgcacgtgcca 
 A3.2 cttcctccgcgggtaccg cactccacgcacgtgcca 
 B57.1 ggccggagtattgggacg cgtcgcagccatacatcac 
 B57.2 accgagagaacctgcggat cgtcgcagccatacatcac 
P7 A1.1 cgacgccgcgagccagaa caggtatctgcggagcccg 
 A1.2 ttcctccgcgggtaccgg gctctctgctgctccgccg 
 A11.1 ggttctcacaccatccagata gctctctgctgctccgccg 
 A11.2 cttcctccgcgggtaccg gctctctgctgctccgccg 
 B35.1 gcaagaccaacacacagactt gccatacatcctctggatga 
 B35.2 cgagagagcctgcggaac gccatacatcctctggatga 
 B60.1 gagccccgcttcatcacc gctctggttgtagtagccgc 
 B60.2 acgccacgagtccgagga gctctggttgtagtagccgc 
 
Figure 1: Detection of microchimerism by nested PCR using HLA class I specific primers. Figure 1A and B represent 
Polaroid pictures of agarose gel of P7 and P5 respectively. Each lane represents a different sample. Sample 1 to 7 are 
dilutions of DNA of the blood donor (positive control) started with 70.000 positive cells (1:1); sample 8 only contains 
negative DNA; sample 9 is the DNA size marker; sample 10 to 17 are patient PBMC of different time periods and water 
controls (C). Figure D shows the sequence of the HLA-A and HLA-B primers for first round PCR and of each 
sequence-specific primer for second round PCR. In second round PCR, two different primer combinations are used for 
each specific HLA molecule.    
 
 
In Figure 1B, representing P5, a clear response was shown in the 2 wk post-transfusion 
samples when using primer combination HLA-A1.1. However, due to positivity of one 
pre-transfusion sample, results obtained with this primer combination are not reliable. 
A slight response was detected after amplification with the HLA-A3.1 primers, but this 
could not be confirmed with the duplicate sample or with any of the other primer 
combinations.  
 
Nested PCR technique 
Frequently, technical problems occurred while using the nested PCR technique. Some 
primer combinations amplificated specific as well as non-specific DNA in a similar 
quantity, as shown by primer combination B60.2 (Figure 1A) and A1.2 (Figure 1B).  
In contrast, other primers did not bind at all (B35.2, Figure 1A).  
D 
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An internal control is the use of pre-transfusion DNA. Only patients who were not 
exposed to alloantigens via pregnancy or therapeutic transfusions were included into 
the pretransplant blood transfusion protocol, which makes the chance of detecting 
microchimeric cells in the pre-transfusion samples very low. Therefore, positive pre-
transfusion samples (as obtained by A1.1 primers, Figure 1B) were regarded as false-
positive, as well as the positive water controls (B60.1, lane 12, Figure 1A). It is clear that 
nested PCR is a very sensitive technique prone to contamination leading to false 
positive results. A more robust and reliable approach for the detection of 
microchimerism is necessary for routinely monitoring of patients. 
 
Flow cytometry-based cell sorting 
HLA specific monoclonal antibodies (mAbs) can be used to distinguish between cells of 
two genetically different individuals using flowcytometry (35). To validate sensitivity 
of using HLA specific antibodies, we mixed pre-transfusion PBMCs of patient 7 (P7) 
and the blood donor (Table 1) in different quantities in order to mimic a microchimeric 
situation. Subsequently, cells were labeled with an anti-HLA-B35 mAb specific for 
donor but not patient cells. The 10% mix was used to define gates for the CD45+CD14-
HLA-B35+ donor cells (pos) as well as the CD45+CD14-HLA-B35- patient cells (neg) 
(Figure 2A). The 0.1% mix was used for cell sorting using the defined gating strategy. 
More than 3x106 events were acquired during cell sorting, resulting in a yield of 2522 
cells in the positive fraction (pos) and 706.266 cells in the negative fraction (neg). The 















Figure 2: Gating strategy and cell sorting. Dotplots of CD45 and HLA-B35 in the 10% (A) and 0.1% (B) donor-patient 
mix. The gates for CD45+CD14-HLA-B35+ donor cells (pos) and CD45+CD14-HLA-B35- patient cells (neg) are set in the 
10% mix (A) and applied to the 0.1% mix (B). The neg and pos fraction of the 0.1% mix (B) are sorted and further 
analyzed in quantitative PCR.  
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As shown in Figure 2B, the analysis of so many cells, which is necessary to sort 
sufficient cells for PCR analyses, hampers a reliable discrimination between patient and 
donor cells. Additional staining of the unwanted (patient) cells with another HLA 
specific mAb (as exclusion marker) can overcome this problem. This is shown in a 
separate experiment, where we prepared a mixture of HLA-A2+ chimeric cells and 
HLA-A3+ bulk cells (1:100) and stained them with HLA specific mAbs (Figure 3). The 
chimeric cell fraction (HLA-A2+A3-) can easily be discriminated and is more pure 
















Figure 3: Gating strategy using two distinct HLA specific mAbs. A 1% mixture of chimeric cells (HLA-A2, -A33, -B62, -
B17, -DR17, -DR15) and bulk cells (HLA-A3, -A11, -B7, -B35, -DR4, -DR13) was prepared and stained with an anti-
HLA-A2 Alexa 647-conjugated mAb, an anti-HLA-A11/A3/A24 biotin-labeled antibody (BRO11F6; both manufactured in 
our lab), and PE-conjugated streptavidin. Chimeric cells are defined as CD45+CD14-HLA-A2+A3- and bulk cells as 
CD45+CD14-HLA-A2-A3+.    
 
 
Real-time PCR  
After sorting the HLA-B35+ donor cells, a real-time PCR was performed to confirm 
donor origin on the DNA level in a quantitative way with primers specific for other 
donor-specific HLA molecules (HLA-A1/11, HLA-DR7). The sorted fractions (pos and 
neg), the artificial 0.1% chimeric cell suspension as well as the original patient and 
blood donor PBMCs were analyzed in real-time PCR. Results of this quantitative assay 
are shown in Figure 4A and depicted as Ct values, which refer to the PCR cycle 
numbers that are necessary to generate a fluorescent signal above a certain threshold. 
The lower the Ct value, the fewer PCR cycles are needed to generate a specific product, 
showing that more specific DNA was present in the starting sample. Since each starting 
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sample contained a variable amount of DNA, this had to be normalized by using 
primers for the house-holding gene human hematopoietic cell kinase (HCK). Figure 4A 
shows that the positive fraction (pos) after sort contained the lowest amount of DNA 
(Ct HCK=19.71) and the blood donor PBMCs the highest amount of DNA (Ct 
HCK=14.76). To correct for DNA input, the Ct value for the HCK gene was subtracted 
from the Ct values obtained after amplification with the donor-specific HLA-A1/A11 or 
HLA-DR7 primers ( Ct). The Ct values are used for comparisons.    
Figure 4A shows that the pre-transfusion sample failed to generate a Ct value while 
using the donor-specific primers, which confirms its suitability as a negative control. 
Blood donor PBMCs serve as a positive control, which is confirmed by a low Ct value 
( Ct A1/A11: 0.06, Ct DR7: 1.88). Higher Ct values were found when less donor cells 
were present, such as in the 0.1% chimeric cell suspension ( Ct A1/A11: 9.42, Ct DR7: 
10.70). As expected, Ct values decreased when using the positive fraction after sort 
containing donor cells ( Ct A1/A11: -0.57, Ct DR7: 0.70) and increased when using the 
negative fraction after sort containing only patient cells ( Ct A1/A11: 9.49, Ct DR7: 
13.53). 
The enrichment of donor cells by flowcytometry-based cell sorting is shown graphically 
in Figure 4B and C. If the Ct value of the 0.1% chimeric pre-sort sample is considered 
as zero, the Ct value of the positive fraction after sort is about ten times lower (note 
the reverse y-axis) and thus contains more donor-specific DNA. Similarly, the negative 
fractions contain less donor-specific DNA, as the Ct values, especially obtained with 
the HLA-DR7 specific primers, are higher as compared to the 0.1% chimeric cell 
suspension.  
Also the 2 wk post-transfusion sample of P7 was taken in the flowcytometry-based cell 
sorting and quantitative PCR analysis. As expected, the Ct value of the positive 
fraction was lower compared with the Ct value of the negative fraction when using 
the HLA-A1/A11 specific primers, however this could not be confirmed with the HLA-
DR7 specific primers (data not shown).  
 
A 
Sample Ct HCK Ct A1/A11 Ct A1/A11 Ct DR7 Ct DR7 
Patient PBMCs pre-transfusion 15.96 n.a. n.a. n.a. n.a. 
Blood donor PBMCs 14.76 14.82 0.06 16.64 1.88 
0.1% chimera pre-sort 15.60 25.02 9.42 26.30 10.70 
Pos after sort 19.71 19.14 -0.57 20.41 0.70 



















Primers 5’ 3’ 
HCK tattagcaccatccataggaggctt gttagggaaagtggagcggaag 
HLA-A1/A11 cgacgccgcgagccagaa caggtatctgcggagcccg 
HLA-DR7 ctgtggcagggtaagtata ccgtagttgtgtctgcacac 
 
Figure 4: Results of the real-time PCR of the sorted fractions, the 0.1% chimeric cell suspension and patient and blood 
donor PBMCs. Figure A depicts the Ct values for each sample using primers that detect DNA from the normalizing 
HCK gene, the HLA-A1/A11 gene or the HLA-DR7 gene. Ct values were calculated by subtracting the Ct value of the 
HCK gene from the Ct value of the specific gene. In Figure B and C the effect of cell sorting is depicted. Sorting the 
donor cells (pos) out of the 0.1% chimeric cell suspension (considered as zero) resulted in a lower Ct value, while 
sorting the negative fraction (neg) revealed a higher Ct value (note the reverse y-axis). The sequences of the forward 





Although it is not clear whether microchimerism is the cause or consequence of 
transplant tolerance, it is widely accepted that a certain degree of tolerance must exist 
in order for donor cells to persist in the recipient’s circulation (15). One of the goals of 
this study was to investigate the occurrence of microchimerism in recipients of a 
leukocyte-containing blood transfusion. In one out of 7 patients we detected leukocytes 
of donor origin in the peripheral blood two weeks after transfusion. In this patient, 
microchimerism was evaluated by the nested PCR technique that is now used for 
microchimerism detection and a new technique that combines flow cytometry-based 
cell sorting and direct PCR.    
The degree to which donor cells survive after allogeneic blood transfusion depends on 
several factors. Microchimerism is thought to develop more often after transfusion of 
traumatic patients with a suppressed immune system (36) and less often after 
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transfusion of HLA-mismatched (11) and irradiated or stored blood products (37). 
Patients in this study received a fresh, non-irradiated, one HLA-DR shared blood 
transfusion, while on dialysis awaiting simultaneous pancreas-kidney transplantation. 
In one out of seven patients, microchimeric cells of donor origin were detected two 
weeks after transfusion by nested PCR (sensitivity: 0.005%) and this was confirmed by 
sequence analysis. None of the patients showed microchimeric donor cells 16 weeks 
after transfusion. Due to the small study population, no conclusions can be drawn yet 
about the prevalence of microchimerism after pretransplant leukocyte-containing blood 
transfusions.   
To be able to detect a low number of donor cells in the recipient’s peripheral 
circulation, a technique has to fulfill strict criteria in order to obtain reliable results. The 
nested PCR technique is characterized by its high sensitivity (31) and is commonly used 
in detection of microchimerism (8,32,35). However, a drawback of the technique is the 
appearance of unexpected amplification products (32). We also found positive bands 
on the gel in the water and negative control samples and even in a few pre-transfusion 
samples, which are the most adequate controls. However, individuals without previous 
pregnancies, transfusions of transplantations are not necessarily negative for 
microchimerism, due to two-way fetal-maternal cell transfer. An underlying problem 
of the extra bands could be contamination of the samples. Amplification of 
contaminating molecules in two successive rounds of PCR can easily be misinterpreted 
to indicate the presence of donor alleles. Currently, we are evaluating the possibility of 
using ultraviolet light for the degradation of contaminating aerosols. Working in an air 
cabinet may be an additional option to reduce the risk of contamination. False-positive 
results can also arise after misannealing of the primers. In many cases, a single 
mismatch at the 3’ residue was not sufficient to prevent mispriming events. Cross 
reactivity of the primers with other HLA molecules is another possibility. In any case, 
the results can be strengthened with an additional nested PCR on other markers than 
HLA, such as the Y-chromosome (if possible) or mitochondrial DNA. Besides the high 
probability of contamination and mispriming events, the nested PCR is a complicated 
and time-consuming technique and not quantitative. Therefore, we developed an 
alternative and more robust approach to detect microchimerism: a flow cytometry-
based method to select the microchimeric cells with HLA-specific monoclonal 
antibodies (mAbs) and confirmation of donor/patient origin with quantitative real-time 
PCR.  
Labeling of mAbs with magnetic beads or fluorescent markers makes it possible to sort 
individual cells with advanced techniques (MACS: magnetic-activated cell separation 
and FACS: fluorescent-activated cell sorting). While a high percentage of cells is lost 
during MACS separation (35), we used the FACS-based method to select microchimeric 
cells for further analysis. Flow cytometry has already been described as a sensitive and 
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valuable technique in the detection of macro- or mixed chimerism, however highly 
specific and good binding antibodies are needed for the detection of a low number 
(<1%) of specific cells (38,39). While using the biotinylated anti-HLA-B35 mAb that was 
manufactured in our own lab, we were able to detect the donor populations in the 10% 
as well as in the 0.1% mixture.  
A real-time PCR technique confirmed the donor origin of the sorted positive fraction 
from the 0.1% mixture. Irrespective of the used primers, DNA product corresponding 
to the donor was detected after less rounds of amplification in case of the positive 
fraction sample as compared to the 0.1% mixture. This direct PCR technique was also 
able to detect 1 donor cell in 1000 patient cells (sensitivity: 0.1%), as the Ct values of 
the 0.1% mixture were lower than the sorted negative fraction and at least detectable in 
contrary to the pre-transfusion sample.  
This chapter proves the principle of the combined approach to detect microchimerism. 
Flow cytometry-based sorting of cells followed by confirmation of donor origin in real-
time PCR was possible for microchimeric cells at a level of 0.1%. At lower 
concentrations of donor cells, more cells have to be counted in order to sort enough 
cells for reliable PCR analyses. We showed that the non-specific binding that occurred 
with increasing numbers of counted cells can be circumvented using an additional 
HLA specific mAb that targets the patient cells. In ongoing experiments this set-up is 
applied to establish the detection limit of the combined approach.  
The advantage of the combined approach is the detection of microchimerism on cell 
level as well as DNA level. This way, the PCR primers can be chosen in such a way that 
they target other donor HLA molecules than the mAbs for flowcytometry, which 
strengthens the outcome of microchimerism detection. Our results showed that donor 
cell sorting facilitates the real-time PCR technique and results in an enriched donor cell 
population that can also be used in further (functional) assays.  
In conclusion, microchimerism after a leukocyte-containing blood transfusion was 
established after two weeks in one patient using the nested PCR technique. In the other 
six patients, donor cells were absent or not detected due to technical limitations. The 
nested PCR is a sensitive technique, but contamination remains a major problem. Our 
proposed approach, combining flow cytometry-based cell sorting and confirmation of 
donor origin by subsequent quantitative PCR analysis, may be a valuable and reliable 
tool for microchimerism detection. As our laboratory has developed more than 100 
human monoclonal antibodies directed against different HLA antigens, it is possible to 
apply this method in almost all allogeneic combinations. Once this assay is validated, it 
is possible to establish the prevalence of microchimerism after pretransplant blood 
transfusions in a reliable way and determine its role in transplantation tolerance.  




1.   Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ 
transplantation: the basis of graft acceptance. Hepatology 1993;17: 1127-1152. 
2.   Starzl TE, Demetris AJ, Trucco M et al. Systemic chimerism in human female recipients of 
male livers. Lancet 1992;340: 876-877. 
3.   Starzl TE, Demetris AJ, Trucco M et al. Chimerism and donor-specific nonreactivity 27 to 
29 years after kidney allotransplantation. Transplantation 1993;55: 1272-1277. 
4.   Suberbielle C, Caillat-Zucman S, Legendre C et al. Peripheral microchimerism in long-
term cadaveric-kidney allograft recipients. Lancet 1994;343: 1468-1469. 
5.   Caillat-Zucman S, Legendre C, Suberbielle C et al. Microchimerism frequency two to thirty 
years after cadaveric kidney transplantation. Hum Immunol 1994;41: 91-95. 
6.   Schlitt HJ, Hundrieser J, Hisanaga M et al. Patterns of donor-type microchimerism after 
heart transplantation. Lancet 1994;343: 1469-1471. 
7.   Kubit V, Sonmez-Alpan E, Zeevi A et al. Mixed allogeneic chimerism in lung allograft 
recipients. Hum Pathol 1994;25: 408-412. 
8.   Knoop C, Andrien M, Defleur V et al. Detection of blood chimerism after lung and heart-
lung transplantation. The superiority of nested as compared with standard polymerase 
chain reaction amplification. Transplantation 1994;58: 1335-1338. 
9.   Adams PT, Davenport RD, Reardon DA, Roth MS. Detection of circulating donor white 
blood cells in patients receiving multiple transfusions. Blood 1992;80: 551-555. 
10.   Lee TH, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor 
leukocytes after allogeneic transfusions in immunocompetent recipients compatible with 
donor cell proliferation. Blood 1995;85: 1207-1214. 
11.   Vervoordeldonk SF, Doumaid K, Remmerswaal EB et al. Long-term detection of 
microchimaerism in peripheral blood after pretransplantation blood transfusion. Br J 
Haematol 1998;102: 1004-1009. 
12.   Lee TH, Paglieroni T, Utter GH et al. High-level long-term white blood cell 
microchimerism after transfusion of leukoreduced blood components to patients 
resuscitated after severe traumatic injury. Transfusion 2005;45: 1280-1290. 
13.   Khosrotehrani K, Bianchi DW. Multi-lineage potential of fetal cells in maternal tissue: a 
legacy in reverse. J Cell Sci 2005;118: 1559-1563. 
14.   Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, 
chimerism, and graft acceptance. Lancet 1992;339: 1579-1582. 
15.   Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol 
Today 1996;17: 584-587. 
16.   Ciancio G, Miller J, Garcia-Morales RO et al. Six-year clinical effect of donor bone marrow 
infusions in renal transplant patients. Transplantation 2001;71: 827-835. 
17.   Bonilla WV, Geuking MB, Aichele P, Ludewig B, Hengartner H, Zinkernagel RM. 
Microchimerism maintains deletion of the donor cell-specific CD8+ T cell repertoire. J Clin 
Invest 2006;116: 156-162. 
18.   Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient 
lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal 
disease. Transplantation 2002;74: 1405-1409. 
Chapter 6 
126 
19.   Pujal JM, Grinyo JM, Gil-Vernet S et al. Early hematopoietic microchimerism predicts 
clinical outcome after kidney transplantation. Transplantation 2007;84: 1103-1111. 
20.   Claas F. Chimerism as a tool to induce clinical transplantation tolerance. Curr Opin 
Immunol 2004;16: 578-583. 
21.   Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-
stimulatory blockade induces macrochimerism and tolerance without cytoreductive host 
treatment. Nat Med 2000;6: 464-469. 
22.   Seung E, Mordes JP, Rossini AA, Greiner DL. Hematopoietic chimerism and central 
tolerance created by peripheral-tolerance induction without myeloablative conditioning. J 
Clin Invest 2003;112: 795-808. 
23.   Graca L, Le MA, Cobbold SP, Waldmann H. Dominant transplantation tolerance. Opinion. 
Curr Opin Immunol 2003;15: 499-506. 
24.   Waanders MM, Roelen DL, Brand A, Claas FH. The putative mechanism of the 
immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the 
alloimmune response. Transfus Med Rev 2005;19: 281-287. 
25.   Bushell A, Pearson TC, Morris PJ, Wood KJ. Donor-recipient microchimerism is not 
required for tolerance induction following recipient pretreatment with donor-specific 
transfusion and anti-CD4 antibody. Evidence of a clear role for short-term antigen 
persistence. Transplantation 1995;59: 1367-1371. 
26.   Sahota A, Gao S, Hayes J, Jindal RM. Microchimerism and rejection: a meta-analysis. Clin 
Transplant 2000;14: 345-350. 
27.   SivaSai KS, Alevy YG, Duffy BF et al. Peripheral blood microchimerism in human liver 
and renal transplant recipients: rejection despite donor-specific chimerism. 
Transplantation 1997;64: 427-432. 
28.   McDaniel HB, Yang M, Sidner RA, Jindal RM, Sahota A. Prospective study of 
microchimerism in transplant recipients. Clin Transplant 1999;13: 187-192. 
29.   Pujal JM, Gallardo D. PCR-based methodology for molecular microchimerism detection 
and quantification. Exp Biol Med (Maywood ) 2008;233: 1161-1170. 
30.   Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 
2004. Tissue Antigens 2005;65: 301-369. 
31.   Carter AS, Cerundolo L, Bunce M et al. Nested polymerase chain reaction with sequence-
specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-
matched individuals. Blood 1999;94: 1471-1477. 
32.   Carter AS, Bunce M, Cerundolo L, Welsh KI, Morris PJ, Fuggle SV. Detection of 
microchimerism after allogeneic blood transfusion using nested polymerase chain reaction 
amplification with sequence-specific primers (PCR-SSP): a cautionary tale. Blood 1998;92: 
683-689. 
33.   Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res 1988;16: 1215. 
34.   Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S. Quantitative 
assessment of retroviral transfer of the human multidrug resistance 1 gene to human 
mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe 
combined immunodeficient mice. Blood 2000;95: 1237-1248. 
35.   Mirabile M.  The detection of microchimerism: strategies and practical problems.  2007.  
Department of Biopathology and Biomedical Methodology, University of Palermo, 
Palermo, Italy. Ref Type: Thesis/Dissertation 
Development of microchimerism after pretransplant blood transfusions 
127 
36.   Utter GH, Owings JT, Lee TH et al. Blood transfusion is associated with donor leukocyte 
microchimerism in trauma patients. J Trauma 2004;57: 702-707. 
37.   Utter GH, Reed WF, Lee TH, Busch MP. Transfusion-associated microchimerism. Vox 
Sang 2007;93: 188-195. 
38.   Dahmen UM, Boettcher M, Krawczyk M, Broelsch CE. Flow cytometric "rare event 
analysis": a standardized approach to the analysis of donor cell chimerism. J Immunol 
Methods 2002;262: 53-69. 
39.   Watanabe N, Takahashi S, Ishige M et al. Recipient-derived cells after cord blood 
transplantation: dynamics elucidated by multicolor FACS, reflecting graft failure and 















The question addressed in this thesis was: does a beneficial effect of pretransplant 
blood transfusions still exists and if so, are we able to unravel the immunological 
mechanism involved with modern in vitro techniques? It is known that blood 
transfusions can lead to immunization or tolerance in the recipient. The latter is 
characterized by an improved transplant outcome after pretransplant blood 
transfusions and was the basis of our research. The first observations of improved 
kidney graft function and survival after blood transfusion date 35 years back (1) and 
were later reported in heart, liver and pancreas-kidney transplantation as well. Despite 
intensive research, no exclusive immunological mechanism has been found. Moreover, 
investigation was hampered by abolition of pretransplant transfusion policies in many 
hospitals that observed an improved transplant outcome due to better rejection 
diagnosis, patient care and immunosuppressive drugs. The fact that late side effects of 
immunosuppressive drugs and chronic graft rejection remain a major problem 
emphasizes the importance of developing tolerance-inducing strategies. If we can 
identify factors that promote transplantation tolerance, graft acceptance may improve 
and immunosuppressive drugs can be withdrawn or reduced. In this respect, 
understanding of the immunological mechanism of the blood transfusion effect would 
be helpful to develop tolerance-inducing strategies. That was the final aim of our 
clinical and fundamental research on the effects of pretransplant blood transfusions.  
 
A summary of clinical studies investigating the effect of pretransplant blood 
transfusions on the occurrence of acute rejection episodes and graft survival after 
kidney, heart, pancreas-kidney and liver transplantation is given in Chapter 1 (Table 3). 
The majority of the studies found a beneficial transfusion effect, but the heterogeneic 
character of the studies should be noted. At the Leiden University Medical Center 
(LUMC), a pretransplant protocolled blood transfusion (PBT) protocol still exists for 
non-immunized patients on the waiting list for simultaneous pancreas-kidney 
transplantation (SPKT). We investigated the effect of this transfusion protocol on the 
occurrence of acute kidney graft rejections and patient and graft survival (Chapter 2). 
The major intervention that was responsible for decreasing the percentage of patients 
with acute rejection episodes of the kidney graft was treatment with induction therapy. 
Development of subsequent graft rejections, defined as more severe rejections that 
require ATG treatment, was prevented by PBTs in 50% of the patients irrespective of 
the use of induction therapy.  
Patients in the LUMC were transfused with a pretransplant blood product that 
contained leukocytes and was matched for one HLA-DR antigen with the recipient. 
Many immunological mechanisms are proposed for the beneficial transfusion effect, 
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but most of these cannot explain the difference between HLA-DR matched and 
mismatched transfusions. In Chapter 3, an immune mechanism is described, which 
may explain the central role for shared HLA-DR molecules in the beneficial transfusion 
effect.   
HLA-DR molecules on antigen presenting cells (APCs) of the transfusion donor can be 
recognized by recipient T cells via the direct (allo HLA) or indirect pathway (self HLA 
+ allopeptide). The observation that HLA-DR sharing between blood donor and 
recipient favors a beneficial transplant outcome, suggests that the indirect way of 
allorecognition is important. While generally accepted assays exist to measure recipient 
T cells with direct allospecificity, a reliable and robust assay for monitoring T cells with 
indirect allospecificity is lacking, although many assays have been described for this 
purpose. With in vitro assays using T cell clones with indirect allospecificity and 
different sources of donor alloantigen, we have analyzed the advantages and pitfalls of 
the published approaches and concluded that a robust assay is still lacking (Chapter 4).   
In an attempt to unravel the immunological mechanism of the blood transfusion effect, 
phenotypic and functional in vitro assays were performed with recipient peripheral 
blood mononuclear cells (PBMCs) before and after an HLA-DR shared PBT (Chapter 5). 
After stimulation with blood donor PBMCs in an Elispot, we detected an increase of 
recipient memory IFN  producing T cells 2 weeks (2wk) after blood transfusion as 
compared to pre-transfusion. This immune activation by PBT was not accompanied by 
changes in phenotypic cell surface or intracellular markers. Additionally, similar 
analyses were performed, but in another pretransplant transfusion setting. Patients 
waiting for living-related kidney transplantation received a donor-specific transfusion 
(DST) in case they had previously been immunized by pregnancy. Again, an increased 
IFN  production was observed 2wk after DST. In contrast to PBT, DST was more potent 
in activating the recipient’s immune system, as increased frequencies of IFN  
producing cells were also found longer after DST and after third party stimulation. 
Phenotypic analysis showed that 2wk post-DST the number of NK cells increased 
significantly, which was accompanied by an increased expression of NK cell-related 
genes in microarray analysis. Moreover, microarray analysis showed many more 
activated immune genes in DST recipients, but not in PBT recipients. The distinct 
immunological profile of PBT and DST recipients (non-immunized versus immunized 
by pregnancy, respectively) may account for the different in vitro observations.  
A feature associated with immunological tolerance after transplantation is 
microchimerism (2). The persistence of a low percentage of donor cells in the recipient 
can lead to transplantation tolerance to other tissues or organ from the same donor, as 
established in rodents, large animal models and humans. Microchimerism after blood 
transfusion may be one of the mechanisms of the beneficial blood transfusion effect 
after transplantation. In Chapter 6 we detected microchimeric cells of blood donor 
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origin in the peripheral blood of a patient 2wk after PBT by use of the nested PCR 
technique. The nested PCR is a highly sensitive assay, but associated with the risk of 
false-positive reactions. Therefore, we developed a new approach that combines 
flowcytometric cell sorting and quantitative PCR. It is based on sorting the chimeric cell 
population by using HLA-specific monoclonal antibodies for subsequent quantitative 
analysis in real-time PCR to confirm donor origin. The principle of this technique is 
described in Chapter 6. Taken together, this thesis includes the first observations of a 
beneficial effect of pretransplant blood transfusions in simultaneous pancreas-kidney 
transplantation. However, despite current available sophisticated in vitro techniques we 
were not able to explain the immunological mechanism involved. In particular, no 
suggestion for regulatory T cell establishment could be found. Our investigations into 
the indirect allorecognition and microchimerism may contribute to the development of 




Clinical evidence for a beneficial blood transfusion effect 
An overview of clinical studies investigating the effect of pretransplant blood 
transfusions on the function and survival of transplanted organs from deceased donors 
is given in Table 3 of Chapter 1. Of the 13 clinical studies that compared patients who 
received a pretransplant blood transfusion with non-transfused patients, eight 
observed less acute rejection episodes and/or improved graft survival after transfusion 
(1,3-9). Within the time-frame of these studies, graft outcome improved as well due to 
better medical facilities, but could still be affected by pretransplant blood transfusions 
(6). Taken into account the presence of leukocytes or sharing of an haplotype or HLA-
DR antigen between blood donor and recipient, possibly promoting 
hyporesponsiveness upon transplantation (10), eight of the eleven studies showed 
better clinical outcome (3,5,11-15). In SPKT, only two retrospective studies have been 
performed, including ours. We found that patients benefit from one unit of HLA-DR 
shared blood before SPKT, as they developed fewer severe acute rejection episodes 
needing treatment with ATG than patients without a pretransplant transfusion (16). In 
the other study only a trend, but not a significantly lower rejection rate after random 
transfusions was found, without improvement of one year graft survival (17).  
In living-related kidney transplantation DSTs have a beneficial effect as well (18). As 
the organ donor is not always selected on basis of HLA compatibility, the blood 
product not necessarily shares an HLA antigen with the recipient. However, blood and 
organ donor are from the same individual, which is thought to promote a beneficial 
outcome (19). Marti et al. depicted the clinical benefit from DST as observed in many 
studies, but also highlighted the heterogeneous character of the studies (18).  
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The huge heterogeneity between the studies (investigating the effect of PBT as well as 
DST) is caused by the time frame of more than 30 years during which many clinical 
improvements were made. Due to the retrospective character of almost all studies, they 
differ in selection of patients, blood product, presence or absence of various types of 
immunosuppressive coverage and duration of follow-up. While outcome after 
transplantation depends on several factors that cannot be controlled in a retrospective 
study, it is difficult to attribute a favorable effect to a pretransplant blood transfusion, 
especially in studies that did not include a control group or based their conclusions on 
historical control groups. Also in our retrospective study a good control group (without 
pregnancy or therapeutic transfusions) is lacking.  
Although well-designed observational studies with a retrospective character are 
valuable in clinical research to generate a hypothesis, randomized controlled trials 
(RCTs) are needed to confirm the assumptions (20). Only three RCTs investigated the 
pretransplant blood transfusion effect in deceased-donor organ transplant recipients 
(see Table 3). Two smaller studies ( 40 patients per group) did not observe a better 
transplant outcome after a random or partly HLA-DR matched transfusion respectively 
(21,22). However, the first one did not take into account acute graft rejection, which is a 
risk factor for chronic rejection and may be missed when looking at 1-year graft 
survival, while the second one may be underpowered to detect an effect of HLA-DR 
shared blood transfusions on graft outcome. The only RCT that observed a clinical 
benefit of pretransplant blood transfusions was a large multi-center study ( 200 
patients per group), where patients experienced less often severe acute rejection 
episodes and a higher 5-year graft survival after having received three randomly 
selected, stored blood products (6). The difference in the outcome parameters between 
transfused and non-transfused patients was however small, less than 10%. In living-
related kidney transplantation, only one small study with a prospective randomized 
design has been performed (23). In that study, 15 patients received a DST 24h pre-
operatively with cyclosporin A coverage and the remaining 15 subjects did not receive 
a DST. The DST group demonstrated significantly fewer acute rejection episodes, a 
markedly better graft function and a clear trend toward a higher 1-year allograft 
survival.  
Although many observational clinical studies observed a possible immunosuppressive 
effect of pretransplant blood transfusions, its effect has not been proven in sufficiently 
powered RCTs.  
 
Determination of an effect of a DST or PBT on transplant outcome requires RCTs 
considering the following factors: 
Selection of a well-designed patient cohort and control group.  
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Power. While transplant outcome is influenced by many factors and a 
pretransplant blood transfusion may be one of these, the study should include 
enough patients to demonstrate a transfusion effect in a multivariate analysis. For 
SPKT in the Netherlands this is impossible, as there are less than 30 
transplantations per year.  
Standardization of the blood product. It is assumed that leukocytes are required 
(3), but in this respect different blood products have been used (whole blood, red 
blood cell concentrates, buffy coat-depleted blood). Additionally, the exact number 
of leukocytes/kg bodyweight recipient in each blood product should be 
standardized. 
Characteristics of the blood product. This depends on the research question. Fresh 
as well as stored blood products have been shown to improve graft outcome, but 
this may be due to different mechanisms. Only one RCT focused on the transfusion 
of a distinct one HLA-DR shared blood product (22), whereas many assumptions 
exist about the relevance of sharing one HLA-DR antigen with the recipient. A RCT 
that have not been performed yet is a RCT that involves one arm with patients who 
received HLA-DR matched blood, one arm with patients who received HLA-DR 
mismatched blood and one arm with non-transfused patients.  
Transfusion protocol. The number of administered products differ in many studies, 
but it has been observed that one unit containing viable leukocytes may already be 
of clinical benefit (3). Also, the time-interval between transfusion and 
transplantation has been questioned before. Blood transfusions given immediately 
before or during the transplantation of organs from deceased donors were less 
effective than blood transfusions given 2wk before transplantation (24), whereas 
one RCT established the opposite effect in recipients of a DST given 24h before 
living-related kidney transplantation (21). An influence on the time-interval in case 
of organ transplantation of deceased donors can however not be managed. 
Immunosuppressive drug therapy. The development of immunosuppressive drugs 
is a continuous process. However, immunosuppressive drug treatment should be 
standardized within one study as it influences transplant outcome to a great extent.  
Follow-up. Most studies investigated the effect of a PBT or DST on acute graft 
rejection and on one-year graft survival. More information can be obtained when 
the occurrence of severe acute graft rejections, chronic rejection and long-term graft 
survival are also analyzed.  
 
Towards the mechanism  
The variety in study characteristics also hampers understanding the possible 
mechanisms of the beneficial effect of pretransplant blood transfusions. Different 
mechanisms have been described explaining the observations that random blood 
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transfusions compared to none and HLA-DR matched transfusions compared to HLA-
DR mismatched transfusions favor transplantation tolerance. 
Elimination or suppression of alloreactive recipient immune cells can occur after the 
transfusion of stored blood products (25). Soluble mediators released upon storage, e.g. 
soluble Fas ligand or soluble HLA molecules, or the lower capacity of antigen 
presentation after storage of donor APCs can turn recipient T cells into anergic cells or 
cells that undergo clonal deletion (25,26). However, as several studies found a 
beneficial effect with fresh (<72h stored) blood products, down-regulation of 
costimulatory signals, occurring after two weeks of storage time, may only be part of 
the mechanism. It can also not explain the differences in transplant outcome following 
HLA-DR compatible versus incompatible blood transfusions.  
 
Pretransplant blood transfusions can have an activating effect (HLA immunization) or 
suppressive effect (27). Our in vitro experiments showed that two weeks after 
transfusion IFN  producing T cells can be found, which is in line with other studies 
(28-31). The question is how these alloreactive recipient T cells would lead to 
hyporesponsiveness towards a subsequent organ donor. Terasaki hypothesized that the 
highly reactive T cell clones that are generated upon a secondary stimulus by 
transplantation are deleted by high-dose immunosuppression (32). The observation 
that some HLA disparity between recipient and transfusion donor is necessary for the 
beneficial transfusion effect fits in this hypothesis (19,33). However, the hypothesis 
cannot explain an improved transplant outcome after HLA-DR matched (for one 
antigen) versus mismatched transfusions. Besides immunosuppressive drugs, 
alloreactive T cells may be suppressed by biological factors, such as regulatory T cells 
(Tregs). In DST treated animals, active suppression by Tregs seemed to play a role, as 
an early immune activation period after transplantation was followed by 
hyporesponsiveness in the later post-transplant period (34). Moreover, it was found 
that tolerated grafts contain dense cellular infiltrates (35) that are even able to kill donor 
target cells (36). It has been shown that Tregs, induced by DST which can transfer 
donor-specific tolerance to naïve animals, require interleukin (IL)-10 for functional 
activity (37) and can regulate in an antigen nonspecific manner (38). Tregs have been 
generated after DST (39), but also following multiple transfusions of blood isolated 
from donor strains unrelated to the eventual allograft donor (40).  
 
The question arises why exposure to allogeneic cells by blood transfusions would 
generate Tregs at all. First, T cell activation may include the Treg compartment, 
influenced by donor cell persistence for sufficient time after blood transfusion in order 
for regulation to develop. The increased percentage of surviving grafts after multiple 
blood transfusions compared with single ones, suggests that after a single blood 
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transfusion donor cells may be cleared before Tregs could be generated (40). However, 
it cannot be excluded that the higher rate of HLA immunization after multiple blood 
transfusions had led to the selection of better matched grafts leading to improved 
survival. Second, the delivery of blood donor-derived alloantigens intravenously may 
engage naturally occurring mechanisms that contribute to normal peripheral tolerance 
(40). If alloantigen recognition takes place in the absence of inflammation or other 
danger signals (41), it may become part of a peripheral tolerance process. Third, it is 
hypothesized that the sharing of HLA-DR antigens between recipient and blood donor 
favors Treg induction (42,43). The shared HLA-DR antigens on donor APCs activate 
recipient CD4+ T cells when they contain a foreign peptide as if presentation on self 
HLA had occurred (indirect alloantigen recognition). Such activated CD4+ T cells 
possess the capability of suppressing other alloreactive cells. CD4+ T cells specific for a 
self-HLA-DR antigen containing a foreign peptide were capable of down-regulating 
autologous cytotoxic T cells via cell lysis or production of the inhibitory cytokine IL-10 
(44). This is in line with the observation that higher IL-10 secretion was observed in a 
mixed lymphocyte culture in case of stimulation with 1 HLA-DR matched cells, in 
contrast to complete HLA-DR disparity (45). A beneficial transplant outcome in 
humans after an one HLA-DR shared blood transfusion may thus rely on the induction 
of Tregs together with a diminished risk of inducing HLA alloantibodies (46) and 
cytotoxic T lymphocytes  (46,47). Similar immunological changes were also observed 
when tolerance was established in the prenatal period (neonatal tolerance). Exposure to 
the non-inherited maternal HLA antigens (NIMAs) on maternal cells during pregnancy 
or breast feeding was associated with a reduced HLA antibody formation against the 
NIMA (48) and a better survival of grafts from donors that were mismatched for the 
NIMA haplotype as compared to the non-inherited paternal HLA antigens (NIPA) (49-
51). Also in case of fetal-maternal tolerance, Tregs are thought to play an important role 
(52). Recently, it was found that CD4+CD25highFoxp3+ Tregs could be generated in utero 
against NIMA, leading to a suppressed fetal anti-maternal immune response (53). In 
some cases, these Tregs even persisted until early childhood.  
 
Although there is evidence that CD4+ T cells with indirect allospecificity can regulate 
other cells, it is still not demonstrated that these CD4+ Tregs are induced in humans by 
a pretransplant blood transfusion. To identify such CD4 populations, we aimed to 
measure T cells with indirect allospecificity in vitro. As extensively discussed in 
Chapter 3, this failed due to lack of reliable tests. Our next approach to detect Tregs 
after pretransplant blood transfusion focused on phenotypic analysis of pre- and post-
transfusion samples. The percentage of Tregs (phenotypically defined as 
CD4+CD25+Foxp3+CD127low cells) remained the same after transfusion in all DST and 
PBT recipients, also after restimulation in vitro with cells from the transfusion donor. 
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We were not able to provide evidence for the induction of Tregs by pretransplant blood 
transfusions. Still, Tregs may play an important functional role, despite this was not 
reflected in an increase in number in the peripheral blood.  
For Tregs to exert their regulatory function, they have to be in close contact with donor-
reactive cells (54). Important sites of action are therefore secondary lymphoid organs 
and the transplanted organ itself. It was described that well-functioning Tregs can be 
found in the peripheral blood, but they may disappear from the periphery to other 
compartments when their suppressive effect is needed locally (55). Animal studies 
showed that donor-specific Tregs induced by DST accumulate in tolerated grafts (56) 
and need a second trigger by the graft for sufficient numbers to develop and protect 
from rejection (57). In humans, a recent study found significantly more Foxp3+ T cells in 
biopsies of renal allografts after DST than without DST, an observation especially 
salient in biopsies with signs of acute rejection (58). A role for DSTs in the recruitment 
of Foxp3+ cells was suggested, but a direct influence of Foxp3 cells on graft survival 
was not established. In this respect, research in man is limited by ethical considerations 
related to sampling graft or lymph node tissue.  
 
Another mechanism that may be involved in the tolerizing pretransplant blood 
transfusion effect is the occurrence of microchimerism, which is the persistence of a low 
number of donor-derived hematopoietic cells. The continuous presence of donor 
antigens may urge the recipient’s immune system into developing central and 
peripheral mechanisms to maintain tolerance for these antigens (2). In the NIMA 
setting, the importance of maternal cell microchimerism was already established. The 
presence of maternal hematopoietic cells in the child, due to bidirectional cell exchange 
during pregnancy (59), was associated with an improved transplant outcome of a 
NIMA-mismatched graft (60,61). In our study, we detected DNA of blood donor origin 
in only 1 out of seven PBT recipients two weeks after transfusion and in none at 
approximately 10 weeks after transfusion. The negative results at 2wk post-transfusion 
obtained in the other 6 patients do not exclude the existence of microchimeric cells, 
because the current techniques hold a risk of contamination and misannealing of the 
primers. In Chapter 6, a new technique that combines enrichment for donor HLA 
expressing cells by flowcytometry-based cell sorting and real-time PCR analysis is 
evaluated and proposed as a promising and valuable tool for future microchimerism 
detection.  
 
Several factors may influence the effect of pretransplant blood transfusions, including 
the patient’s immune status at the moment of transfusion. We analyzed the effect of a 
pretransplant blood transfusion on the cellular immune system of two different 
patients groups that differed in previous exposure to HLA alloantigens. All DST 
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recipients were women who have been pregnant before, while pregnancy and 
therapeutic transfusions were exclusion criteria for PBT recipients. In many studies, 
exact data on the goal of giving a DST, e.g. in vivo cross match or tolerance-induction, 
and on patient selection criteria are lacking. In our study, HLA immunization and 
activation of cellular immunity occurred more frequently after DST compared to PBT. 
It is possible that the increased number and effector function of NK cells that was 
observed after DST, was influenced by the number of IFN  producing T cells 2 wk post-
DST. The difference in response towards PBT or DST is reflected in microarray analysis 
that showed a change in significantly more genes after DST than PBT, which is most 
likely the result of previous immunological priming to foreign HLA in the DST group.  
Another factor that may interfere with tolerance induction in transplantation is the 
immunosuppressive drug therapy that all transplant patients receive. Although we 
observed less severe rejection after pretransplant transfusion despite the use of potent 
immunosuppressive drugs (16), the drugs may destroy the recipient’s immune cells 
including tolerance-promoting Tregs. It is therefore essential to determine which 
immunosuppressive protocols block Tregs generation and which protocols do not. 
Cyclosporin A is reported to abrogate the generation of Tregs (62,63), whereas 
rapamycin is thought to save or even promote the Treg pool (64).  
Moreover, one has to take into account heterologous immunity that may be a barrier to 
tolerance induction (65). Memory cells that are elicited by certain viruses can enhance 
the clearance of unrelated pathogens (66). In the field of transplantation this could 
imply that virus-induced T cells may cross react with donor alloantigens and mediate 
graft rejection. It was shown in a mouse-model that heterologous immunity abrogated 
transplant tolerance that was established after DST in combination with anti-CD154 
antibodies (67). Thus, differences in immune history may be the reason that tolerance 
does not develop in every patient following tolerance-inducing treatment.  
 
Future perspectives of pretransplant blood transfusions   
At the Leiden University Medical Center, two pretransplant transfusion policies 
existed. Pretransplant blood transfusions in the SPKT setting are associated with fewer 
patients with severe acute rejection episodes, as showed in chapter 2. The prevention of 
ATG rejection treatment after PBT diminishes the chance of developing 
immunosuppressive drug-related side effects. At the LUMC, the intention of the DST 
protocol was to act as an in vivo cross-match for women who have been pregnant. The 
decision of continuing the transplantation is based on the fact whether donor specific 
antibodies are induced by the DST. However, cellular reactivity was observed in almost 
every DST recipient as well and may hamper good graft function as well. Based upon a 
study in the Netherlands that showed a profound antibody induction after DST 
together with a lack of beneficial transplant outcome (68), the DST protocol was 
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abandoned in 2007. Apparently, hardly any confidence exists in a future application of 
pretransplant transfusions, as many centers abandoned the pretransplant blood 
transfusion policy. The missed opportunity to conduct well-designed RCTs and the 
lack of understanding the mechanisms contributed to this action.  
 
The ultimate goal in clinical transplantation is the development of protocols that 
provide stable, long-term graft survival independent of immunosuppressive drug 
therapy. To be able to determine a state of tolerance in an individual patient that allows 
withdrawal of immunosuppressive drugs, reliable in vitro assays are necessary that can 
predict B and T cell alloreactivity. However, standardized and sophisticated techniques 
are still lacking (69) and difficult to develop as confirmed by our in vitro studies. 
Nevertheless, our investigations into the indirect allorecognition and microchimerism 
may be valuable for further research.  
A major point that supports the caution of transfusion allogeneic blood to individuals 
is the risk of developing alloantibodies that may hamper subsequent transplantation 
and the transmitting of infectious diseases (70). However, all blood products in the 
Netherlands are screened for many infectious agents and alloimmunization in our 
study was low.  
 
This thesis started with the observation that fewer patients developed severe acute 
kidney graft rejection episodes in case they received a PBT before SPKT. This 
observation remained present in patients who received immunosuppressive induction 
therapy upon transplantation, which suggests that pretransplant blood transfusions 
may still be of benefit. However, to justify the pretransplant use of blood transfusions, 
well-designed RCTs are needed as well as reliable assays that can be used in the field of 
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Klinische en immunologische aspecten van pretransplantatie bloedtransfusies 
 
Inleiding 
Bloedtransfusies worden in de meeste gevallen gegeven aan patiënten die een tekort 
hebben aan rode bloedcellen of bloedplaatjes ten gevolge van een ernstige bloeding of 
bij een gestoorde bloedaanmaak bijvoorbeeld door chemotherapie of een chronische 
bloedziekte. De gewenste effecten van een bloedtransfusie kunnen echter ook gepaard 
gaan met ongewenste bijwerkingen, omdat het bloed van de bloeddonor als vreemd 
wordt gezien door het afweer (immuun) systeem van de ontvanger. De ontvanger 
immuuncellen kunnen geactiveerd worden en antistoffen gaan maken tegen de 
vreemde moleculen (onder andere humane leukocyten antigenen, HLA, genoemd) van 
de bloeddonor, maar ze kunnen ook juist inactief, ofwel tolerant worden. Een 
voorbeeld van het induceren van tolerantie door bloedtransfusies is de betere functie 
en overleving van een transplantaat in patiënten die voorafgaand aan de transplantatie 
een bloedtransfusie hebben ontvangen. De eerste observaties van een verbeterde nier 
transplantaatoverleving na een pretransplantatie bloedtransfusie dateren van 1973. 
Daarna werd eenzelfde effect van pretransplantatie bloedtransfusies gevonden bij hart 
en lever transplantatie. Aangenomen wordt dat de witte bloedcellen (leukocyten) van 
de bloeddonor een belangrijke rol spelen bij dit gunstige bloedtransfusie-effect, maar 
een eenduidig immunologisch mechanisme dat dit effect kan verklaren is nog niet 
gevonden. Onderzoek naar dit mechanisme werd bovendien bemoeilijkt door 
verbetering van de transplantaatoverleving door andere factoren, zoals een verbetering 
van de diagnose van transplantaatafstoting, van patiëntenzorg en 
afweeronderdrukkende medicijnen (immuunsuppressiva). In veel transplantatiecentra 
werd daarom de waarde van een pretransplantatie bloedtransfusie als miniem 
beschouwd en, mede omdat transfusies infecties zoals het HIV konden overbrengen, 
afgeschaft. Echter, chronische transplantaatafstoting en bijwerkingen ten gevolge van 
het gebruik van immuunsuppressiva blijven een probleem voor 
transplantatiepatiënten. Dit benadrukt de behoefte aan inzicht in de wijze waardoor op 
een natuurlijke manier tolerantie geïnduceerd kan worden. Als bekend is welke 
factoren tolerantie kunnen bevorderen, kunnen op den duur de immuunsuppressiva 
afgebouwd worden en zou een belangrijke gezondheidswinst te behalen zijn voor 
transplantatiepatiënten, gezien de vatbaarheid voor infecties en kwaadaardige tumoren 
ten gevolge van immuunsuppressiva.  
In dit proefschrift hebben we ons gericht op de vraag of een gunstig effect van 
pretransplantatie bloedtransfusies optreedt na nier-pancreas transplantatie en zo ja, 




In Hoofdstuk 1 van dit proefschrift (Tabel 3) wordt een overzicht gegeven van alle 
klinische studies die onderzoek hebben gedaan naar het effect van pretransplantatie 
bloedtransfusies na een nier-, hart-, nier-pancreas- of levertransplantatie. Het 
merendeel van de studies beschrijft een gunstig effect (minder acute afstoting of een 
betere transplantaatoverleving) na een pretransplantatie bloedtransfusie, maar het 
heterogene karakter van de studies moet in ogenschouw genomen worden. Het 
bloedproduct dat gebruikt is in deze studies verschilt in type (hoeveelheid leukocyten), 
aantal getransfundeerde eenheden en HLA overeenkomst, waardoor een vergelijking 
tussen studies onderling niet mogelijk is.  
In het Leids Universitair Medisch Centrum (LUMC) wordt een pretransplantatie 
protocollaire bloedtransfusie (PBT) met als doel tolerantie-inductie gegeven aan 
patiënten die op de wachtlijst staan voor een nier-pancreas transplantatie en nooit 
eerder zwanger zijn geweest of een bloedtransfusie hebben ontvangen. In hoofdstuk 2 
beschrijven wij het effect van een dergelijke bloedtransfusie op het voorkomen van 
acute afstoting van het nier transplantaat en de patiënt- en transplantaatoverleving. 
Gedurende de periode van dit retrospectieve onderzoek werd inductie therapie 
ingevoerd. Hoewel deze inductie therapie (een eenmalige hoge dosering van een 
immuunsuppressivum ten tijde van transplantatie) leidde tot een significante 
vermindering van het aantal patiënten met acute afstoting, traden na een PBT bij 
significant minder patiënten ernstige acute afstotingsverschijnselen op. Hierdoor kon 
bij een deel van de patiënten behandeling met sterke immuunsuppressiva na 
transplantatie voorkomen worden.  
 
Immunologisch mechanisme 
Het bloedproduct dat gegeven werd aan de nier-pancreas transplantatie patiënten 
bevatte leukocyten. De bloeddonor werd geselecteerd op basis van een overeenkomst 
(match) in een bepaald type HLA antigenen, de HLA-DR antigenen. Eerder is al 
beschreven dat bloedtransfusies die zijn gematcht voor 1 HLA-DR antigen een 
gunstiger effect veroorzaken dan bloedtransfusies zonder een HLA-DR match. Het 
immunologisch mechanisme dat verantwoordelijk kan zijn voor dit verschil wordt 
gegeven in Hoofdstuk 3. Hierin staat de rol van de HLA-DR gematchte 
pretransplantatie bloedtransfusie centraal. De hypothese is dat een HLA-DR gematchte 
bloedtransfusie leidt tot de vorming van regulatoire T cellen in de ontvanger die de 
immuunrespons tegen een orgaan transplantaat vervolgens kunnen onderdrukken.  
 
De HLA antigenen op de leukocyten van de bloeddonor kunnen op twee manieren 
herkend worden door de immuuncellen van de ontvanger: op de directe en de 
indirecte manier. In het eerste geval wordt het gehele HLA molecuul van de donor 
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herkend door het immuunsysteem van de ontvanger. In het tweede geval worden 
peptiden (stukjes eiwit) afkomstig van het HLA van de donor gebonden aan het HLA 
van de ontvanger en als vreemd herkend in de eigen HLA moleculen van de 
ontvanger. Dit wordt ook wel de indirecte herkenning genoemd. Omdat een 
overeenkomst in HLA-DR molecuul (hetzelfde HLA molecuul van de ontvanger is ook 
aanwezig bij de donor) leidt tot een betere transplantaat uitkomst, is het zeer 
waarschijnlijk dat de indirecte herkenning een belangrijke rol speelt. Of de indirecte 
herkenning van donormoleculen daadwerkelijk leidt tot tolerantie-inductie moet 
blijken uit in vitro testen. In Hoofdstuk 4 beschrijven wij de mogelijkheden en de 
valkuilen in het ontwikkelingsproces van een in vitro test voor de indirecte herkenning.  
Door perifere bloed mononucleaire cellen van de patiënt te bestuderen voor en na (2 
weken en >10 weken) een HLA-DR gematchte PBT, hebben we onderzocht of en op 
welke manier de bloedtransfusie de immuuncellen van de patiënt beïnvloedt 
(Hoofdstuk 5). Met behulp van een Elispot assay kunnen we de mate van cel activatie 
bepalen door de interferon-  (IFN ) productie te meten. Een hoge productie van IFN  
duidt op cel activatie; een lagere productie van IFN  kan veroorzaakt worden door 
regulatoire cellen of mechanismen die de cel onderdrukken.  
We zagen dat 2 weken na transfusie na stimulatie met cellen van de bloeddonor, meer 
specifieke immuuncellen (T cellen) IFN  gaan produceren in tegenstelling tot 
immuuncellen van voor de transfusie. Dit duidt op een activatie van het 
immuunsysteem van de patiënt. Deze activatie ging niet gepaard met fenotypische 
veranderingen, dat wil zeggen veranderingen in markers op de buitenkant van de cel. 
Dezelfde experimenten hebben we uitgevoerd met cellen van de patiënt voor en na een 
pretransplantatie bloedtransfusie, maar nu in een andere setting. Patiënten op de 
wachtlijst voor een nier-transplantaat van een levende donor kregen in het LUMC een 
donor-specifieke transfusie (DST) in het geval ze ooit zwanger waren geweest. In het 
geval van een DST, is de bloeddonor gelijk aan de mogelijke orgaandonor. In de Elispot 
test lieten ook de DST patiënten meer IFN  productie zien 2 weken na DST, maar ook 
lang na DST (>10 weken) en na niet-specifieke stimulatie met cellen van een andere 
donor. Fenotypische analyse liet zien dat het aantal ‘natural killer’ (NK) cellen toenam 
2 weken na DST. Dit werd bevestigd door een andere techniek op gen-niveau 
(microarray analyse), die overigens ook een toename liet zien in verschillende andere 
genen. Het verschil in immunologisch profiel tussen PBT en DST ontvangers (al dan 
niet voorgaande blootstelling aan vreemde moleculen tijdens zwangerschap) is 
mogelijk verantwoordelijk voor de verschillen in uitkomst van de in vitro testen. Het 
klinische gunstige effect op transplantaatuitkomst dat na PBT is gevonden, is echter 
niet gevonden bij patiënten die in Nederland een DST hebben ontvangen. 
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Microchimerisme na bloedtransfusie speelt mogelijk een rol bij het gunstige effect na 
pretransplantatie bloedtransfusies. Microchimerisme, het blijvend voorkomen van een 
laag percentage (<1%) donor cellen in de patiënt, wordt geassocieerd met tolerantie na 
transplantatie.  
We onderzochten de hypothese dat de continue aanwezigheid van donorcellen in de 
patiënt het immuunsysteem van de patiënt dwingt mechanismen te ontwikkelen 
waardoor de patiënt tolerant wordt. In Hoofdstuk 6 beschrijven we dat we 
microchimere cellen hebben gevonden in slechts 1 PBT ontvanger, 2 weken na 
transfusie. Dit kan het gevolg zijn van ongevoeligheid van de testen om chimerisme 
aan te tonen. We beschrijven onze ervaringen met de zogenaamde nested PCR techniek 
en doen een voorstel voor een nieuwe techniek die op een meer betrouwbare manier in 
staat zal zijn microchimere cellen te detecteren. Deze nieuwe techniek combineert het 
verrijken van cellen met behulp van de flowcytometer gevolgd door een kwantitatieve 
DNA test op het geselecteerde product waarvan chimerisme verwacht wordt met 
behulp van HLA specifieke monoklonale antilichamen.  
 
Conclusie 
Dit proefschrift laat zien dat ook na een nier-pancreas transplantatie een klinisch 
gunstig effect kan ontstaan ten gevolge van een pretransplantatie bloedtransfusie. 
Bovendien blijft dit gunstige effect zichtbaar ten tijde van het gebruik van potente 
immuunsuppressiva. Onze in vitro experimenten laten zien dat het immuunsysteem 
van de ontvanger geactiveerd wordt, maar het is nog niet duidelijk wanneer en op 
welke manier dit omslaat naar tolerantie voor de orgaandonor. Duidelijkheid over de 
betrokken immunologische mechanismen vergt betrouwbare en specifieke in vitro 
technieken, die tot op heden nog maar beperkt beschikbaar zijn. In dit opzicht draagt 
ons onderzoek naar de indirecte herkenning van vreemde antigenen en het ontstaan 
van microchimerisme bij aan het inzicht in de immuunprocessen die op gang komen na 
bloedtransfusie of transplantatie. Een toekomst voor pretransplantatie bloedtransfusies 
in de academische centra zal alleen bestaan indien klinische studies in de vorm van 
gerandomiseerde klinische trials een gunstig effect laten zien en wanneer meer inzicht 
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